-- Data for Name: sequence_location; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.sequence_location (id, version, name, chromosomelocation, genelocation, proteinlocation, genesymbol, dbsnpid, "position") FROM stdin;
777293	91	G1069R	g.117611646G>A	g.150863G>A	p.G1069R	CFTR	rs200321110	117611646
777294	91	R1070Q	g.117611650G>A	g.150867G>A	p.R1070Q	CFTR	rs78769542	117611650
777297	91	D1152H	g.117614699G>C	g.153916G>C	p.D1152H	CFTR	rs75541969	117614699
777306	91	3849+10kbC- >T/ Class: V	g.117639961C>T	g.179178C>T	Intronic	CFTR	rs75039782	117639961
777298	91	G1244E	g.117642451G>A	g.181668G>A	p.G1244E	CFTR	rs267606723	117642451
777300	91	S1255P	g.117642483T>C	g.181700T>C	p.S1255P	CFTR	rs121909041	117642483
777301	91	D1270N	g.117642528G>A	g.181745G>A	p.D1270N	CFTR	rs11971167	117642528
777302	91	G1349D	g.117664770G>A	g.203987G>A	p.G1349D	CFTR	rs193922525	117664770
777389	91	64C>T	g.40991369C>T	g.5071C>T	p.R22C	CYP2B6	rs8192709	40991369
777395	91	12710T>A	g.41004015T>A	g.17717T>A	p.Y62X	CYP2B6	rs281864907	41004015
777396	91	12820G>A	g.41004125G>A	g.17827G>A	p.G99E	CYP2B6	rs36060847	41004125
2899031	44	12828G>A	g.41004133G>A	g.17835G>A	p.A102T	CYP2B6	rs148009906	41004133
2899035	44	13075C>T	g.41004380C>T	g.18082C>T	p.R140W	CYP2B6	rs535039125	41004380
5997181	3	13130G>A	g.41004435G>A	g.18137G>A	p.R158Q	CYP2B6	rs141666881	41004435
2899052	44	21088T>C	g.41012393T>C	g.26095T>C	p.Y354H	CYP2B6	rs754621576	41012393
948023	83	3531delAGAAATGGAA	g.94942213_94942222del	g.9056_9065del	p.K118fs	CYP2C9	rs1304490498	94942213
828074	90	786G>A	m.786G>A	\N	\N	MT-RNR1	\N	786
896589	85	807A>C; 807A>G	m.807A>C; m.807A>G	\N	\N	MT-RNR1	\N	807
828078	90	839A>G	m.839A>G	\N	\N	MT-RNR1	\N	839
828079	90	896A>G	m.896A>G	\N	\N	MT-RNR1	\N	896
896595	85	960C>del	m.960delC	\N	\N	MT-RNR1	\N	960
896596	85	961T>G	m.961T>G	\N	\N	MT-RNR1	rs3888511	961
1104230	79	961T>del; 961T>del+Cn	m.961delT; m.961delTinsC(n)	\N	\N	MT-RNR1	rs1556422499	961
828086	90	988G>A	m.988G>A	\N	\N	MT-RNR1	\N	988
828087	90	1095T>C	m.1095T>C	\N	\N	MT-RNR1	rs267606618	1095
828088	90	1189T>C	m.1189T>C	\N	\N	MT-RNR1	rs28358571	1189
828089	90	1243T>C	m.1243T>C	\N	\N	MT-RNR1	rs28358572	1243
2899053	44	21089A>G	g.41012394A>G	g.26096A>G	p.Y354C	CYP2B6	rs780991919	41012394
6234974	1	17839A>G	g.94780544A>G	g.22864A>G	p.N176S	CYP2C19	rs57700608	94780544
5763442	5	3158G>T	g.42127634C>A	g.8177G>T	p.R329L	CYP2D6	rs3915951	42127634
5175088	10	893G>A	g.42129899C>T	g.5912G>A	p.R64H	CYP2D6	rs1415188318	42129899
5175073	10	9_10insA	g.42130783dup	g.5028dup	p.E4fs	CYP2D6	rs1240247139	42130783
828073	90	747A>G	m.747A>G	\N	\N	MT-RNR1	\N	747
828090	90	1494C>T	m.1494C>T	\N	\N	MT-RNR1	rs267606619	1494
828091	90	1520T>C	m.1520T>C	\N	\N	MT-RNR1	\N	1520
828092	90	1537C>T	m.1537C>T	\N	\N	MT-RNR1	\N	1537
828093	90	1555A>G	m.1555A>G	\N	\N	MT-RNR1	rs267606617	1555
828094	90	1556C>T	m.1556C>T	\N	\N	MT-RNR1	\N	1556
779251	91	35230A>G	g.21176804A>G	g.50611A>G	p.N130D	SLCO1B1	rs2306283	21176804
779253	91	35294A>G	g.21176868A>G	g.50675A>G	p.N151S	SLCO1B1	rs2306282	21176868
1002598	81	35297G>A	g.21176871G>A	g.50678G>A	p.R152L	SLCO1B1	\N	21176871
779254	91	35305C>A	g.21176879C>A	g.50686C>A	p.P155T	SLCO1B1	rs11045819	21176879
779255	91	35309A>G	g.21176883A>G	g.50690A>G	p.E156G	SLCO1B1	rs72559745	21176883
1002601	81	35324G>T	g.21176898G>T	g.50705G>T	splicing defect	SLCO1B1	rs77271279	21176898
1002602	81	37038A>G	g.21178612A>G	g.52419A>G	p.Y173C	SLCO1B1	rs141467543	21178612
779256	91	37041T>C	g.21178615T>C	g.52422T>C	p.V174A	SLCO1B1	rs4149056	21178615
779260	91	37383A>G	g.21178957A>G	g.52764A>G	p.I222V	SLCO1B1	rs79135870	21178957
779261	91	55377A>G	g.21196951A>G	g.70758A>G	p.I245V	SLCO1B1	rs11045852	21196951
1002606	81	55401C>T	g.21196975C>T	g.70782C>T	p.R253X	SLCO1B1	rs183501729	21196975
779262	91	55402G>A	g.21196976G>A	g.70783G>A	p.R253Q	SLCO1B1	rs11045853	21196976
1002608	81	58970C>G	g.21200544C>G	g.74351C>G	p.P336R	SLCO1B1	rs72559747	21200544
779263	91	59021T>C	g.21200595T>C	g.74402T>C	p.I353T	SLCO1B1	rs55901008	21200595
779265	91	60981C>G	g.21202555C>G	g.76362C>G	p.F400L	SLCO1B1	rs59113707	21202555
779266	91	61075A>G	g.21202649A>G	g.76456A>G	p.N432D	SLCO1B1	rs56387224	21202649
779267	91	61090G>A	g.21202664G>A	g.76471G>A	p.G437R	SLCO1B1	rs142965323	21202664
779268	91	64347A>G	g.21205921A>G	g.79728A>G	p.D462G	SLCO1B1	rs72559748	21205921
779269	91	64425G>C	g.21205999G>C	g.79806G>C	p.G488A	SLCO1B1	rs59502379	21205999
1002616	81	64457A>G	g.21206031A>G	g.79838A>G	p.I499V	SLCO1B1	rs74064213	21206031
777281	91	S549N	g.117587800G>A	g.127017G>A	p.S549N	CFTR	rs121908755	117587800
777305	91	3272-26A->G	g.117611555A>G	g.150772A>G	Intronic	CFTR	rs76151804	117611555
777290	91	F1052V	g.117611595T>G	g.150812T>G	p.F1052V	CFTR	rs150212784	117611595
777291	91	K1060T	g.117611620A>C	g.150837A>C	p.K1060T	CFTR	rs397508513	117611620
777292	91	A1067T	g.117611640G>A	g.150857G>A	p.A1067T	CFTR	rs121909020	117611640
777295	91	R1070W	g.117611649C>T	g.150866C>T	p.R1070W	CFTR	rs202179988	117611649
777296	91	F1074L	g.117611663T>A	g.150880T>A	p.F1074L	CFTR	rs186045772	117611663
777299	91	S1251N	g.117642472G>A	g.181689G>A	p.S1251N	CFTR	rs74503330	117642472
828077	90	827A>G	m.827A>G	\N	\N	MT-RNR1	rs28358569	827
828080	90	930A>G	m.930A>G	\N	\N	MT-RNR1	\N	930
828081	90	951G>A	m.951G>A	\N	\N	MT-RNR1	rs200887992	951
5997750	3	2460G>A	g.42128332C>T	g.7479G>A	p.V229I	CYP2D6	rs993385303	42128332
5997761	3	1916G>A	g.42128876C>T	g.6935G>A	p.G192R	CYP2D6	rs538707090	42128876
777420	91	18803C>A	g.41010108C>A	g.23810C>A	p.L313I	CYP2B6	rs193922917	41010108
777410	91	21011T>C	g.41012316T>C	g.26018T>C	p.I328T	CYP2B6	rs28399499	41012316
777411	91	21034C>T	g.41012339C>T	g.26041C>T	p.R336C	CYP2B6	rs34826503	41012339
777412	91	21160C>T	g.41012465C>T	g.26167C>T	p.R378X	CYP2B6	rs34097093	41012465
2899055	44	21161G>A	g.41012466G>A	g.26168G>A	p.R378Q	CYP2B6	rs200458614	41012466
2899056	44	21166T>C	g.41012471T>C	g.26173T>C	p.Y380H	CYP2B6	rs201500445	41012471
2899057	44	21173T>A	g.41012478T>A	g.26180T>A	p.I382N	CYP2B6	rs200238771	41012478
777413	91	21388T>A	g.41012693T>A	g.26395T>A	p.I391N	CYP2B6	rs35979566	41012693
5997804	3	912C>A	g.42129880G>T	g.5931C>A	p.S70R	CYP2D6	rs1477736084	42129880
777270	91	R74W	g.117509089C>T	g.48306C>T	p.R74W	CFTR	rs115545701	117509089
777271	91	D110E	g.117530955C>A	g.70172C>A	p.D110E	CFTR	rs397508537	117530955
777272	91	D110H	g.117530953G>C	g.70170G>C	p.D110H	CFTR	rs113993958	117530953
777387	91	-82T>C	g.40991224T>C	g.4926T>C	\N	CYP2B6	rs34223104	40991224
777388	91	62A>T	g.40991367A>T	g.5069A>T	p.Q21L	CYP2B6	rs34883432	40991367
777390	91	76A>T	g.40991381A>T	g.5083A>T	p.T26S	CYP2B6	rs33973337	40991381
777391	91	83A>G	g.40991388A>G	g.5090A>G	p.D28G	CYP2B6	rs33980385	40991388
777392	91	85C>A	g.40991390C>A	g.5092C>A	p.R29S	CYP2B6	rs33926104	40991390
777393	91	86G>C	g.40991391G>C	g.5093G>C	p.R29P	CYP2B6	rs34284776	40991391
777394	91	136A>G	g.40991441A>G	g.5143A>G	p.M46V	CYP2B6	rs35303484	40991441
777397	91	12853G>T	g.41004158G>T	g.17860G>T	p.G110V	CYP2B6	rs186335453	41004158
777398	91	12998T>C	g.41004303T>C	g.18005T>C	p.I114T	CYP2B6	rs139801276	41004303
777399	91	13072A>G	g.41004377A>G	g.18079A>G	p.K139E	CYP2B6	rs12721655	41004377
777400	91	13076G>A	g.41004381G>A	g.18083G>A	p.R140Q	CYP2B6	rs35773040	41004381
777401	91	13101G>T	g.41004406G>T	g.18108G>T	p.E148D	CYP2B6	rs145884402	41004406
777402	91	15614C>G	g.41006919C>G	g.20621C>G	p.P167A	CYP2B6	rs3826711	41006919
777403	91	15618C>T	g.41006923C>T	g.20625C>T	p.T168I	CYP2B6	rs36056539	41006923
777404	91	15631G>T	g.41006936G>T	g.20638G>T	p.Q172H, splice defect	CYP2B6	rs3745274	41006936
2899041	44	15662G>A	g.41006967G>A	g.20669G>A	p.V183I	CYP2B6	rs58871670	41006967
777417	91	15663T>G	g.41006968T>G	g.20670T>G	p.V183G	CYP2B6	rs373489637	41006968
777405	91	15708T>C	g.41007013T>C	g.20715T>C	p.M198T	CYP2B6	rs36079186	41007013
777421	91	21435G>A	g.41012740G>A	g.26442G>A	p.A407T	CYP2B6	rs193922918	41012740
777414	91	21498C>A	g.41012803C>A	g.26505C>A	p.P428T	CYP2B6	rs35010098	41012803
2899061	44	25347G>A	g.41016652G>A	g.30354G>A	p.R434Q	CYP2B6	rs764288403	41016652
2899062	44	25374G>A	g.41016679G>A	g.30381G>A	p.R443H	CYP2B6	rs374099483	41016679
777415	91	25421A>G	g.41016726A>G	g.30428A>G	p.M459V	CYP2B6	rs3211369	41016726
2899064	44	25436G>A	g.41016741G>A	g.30443G>A	p.A464T	CYP2B6	rs117872433	41016741
777418	91	25473G>A	g.41016778G>A	g.30480G>A	p.G476D	CYP2B6	rs564083989	41016778
1102587	79	25505C>A; 25505C>T	g.41016810C>A; g.41016810C>T	g.30512C>A; g.30512C>T	p.R487S; p.R487C	CYP2B6	rs3211371	41016810
6235088	1	3558C>T	g.94942240C>T	g.9083C>T	p.S127F	CYP2C9	rs530507053	94942240
6235110	1	10502T>C	g.94949184T>C	g.16027T>C	p.M240T	CYP2C9	rs369745682	94949184
6235120	1	33512A>C	g.94972194A>C	g.39037A>C	p.T304P	CYP2C9	rs546318684	94972194
5997713	3	3199C>G; 3199C>T	g.42127593G>C; g.42127593G>A	g.8218C>G; g.8218C>T	p.R343G; p.R343W	CYP2D6	rs267608295	42127593
5997724	3	2950C>T	g.42127842G>A	g.7969C>T	p.R329C	CYP2D6	rs150216909	42127842
2899044	44	18008A>C	g.41009313A>C	g.23015A>C	p.H247P	CYP2B6	\N	41009313
777406	91	18045C>A	g.41009350C>A	g.23052C>A	p.S259R	CYP2B6	rs45482602	41009350
777407	91	18053A>G	g.41009358A>G	g.23060A>G	p.K262R	CYP2B6	rs2279343	41009358
777408	91	18701G>C	g.41010006G>C	g.23708G>C	p.A279P	CYP2B6	rs139029625	41010006
777409	91	18783C>G	g.41010088C>G	g.23790C>G	p.T306S	CYP2B6	rs34698757	41010088
2406845	53	c.835A>G;c.835A>T	g.154533605T>C;g.154533605T>A	g.18968A>G;g.18968A>T	p.T279A;p.T279S	G6PD	\N	154533605
777500	91	50T>C	g.94762755T>C	g.5075T>C	p.L17P	CYP2C19	rs55752064	94762755
777501	91	55A>C	g.94762760A>C	g.5080A>C	p.I19L	CYP2C19	rs17882687	94762760
777502	91	83A>T	g.94762788A>T	g.5108A>T	p.K28I	CYP2C19	rs1564656981	94762788
777503	91	151A>G	g.94762856A>G	g.5176A>G	p.S51G	CYP2C19	rs1564657013	94762856
777504	91	12401C>T	g.94775106C>T	g.17426C>T	p.R73C	CYP2C19	rs145328984	94775106
777505	91	12416C>T	g.94775121C>T	g.17441C>T	p.H78Y	CYP2C19	rs1564660997	94775121
777506	91	12455G>C	g.94775160G>C	g.17480G>C	p.G91R	CYP2C19	rs118203756	94775160
777507	91	12480A>G	g.94775185A>G	g.17505A>G	p.H99R	CYP2C19	rs1288601658	94775185
777508	91	12662A>G	g.94775367A>G	g.17687A>G	splicing defect	CYP2C19	rs12769205	94775367
777509	91	12711T>C	g.94775416T>C	g.17736T>C	p.W120R	CYP2C19	rs41291556	94775416
777513	91	12802G>A	g.94775507G>A	g.17827G>A	p.R150H	CYP2C19	rs58973490	94775507
777514	91	17869G>C	g.94780574G>C	g.22894G>C	p.R186P	CYP2C19	rs140278421	94780574
777515	91	17874G>A	g.94780579G>A	g.22899G>A	p.D188N	CYP2C19	rs370803989	94780579
777516	91	17948G>A	g.94780653G>A	g.22973G>A	p.W212X	CYP2C19	rs4986893	94780653
777517	91	19153C>T	g.94781858C>T	g.24178C>T	p.P227L	CYP2C19	rs6413438	94781858
777518	91	19154G>A	g.94781859G>A	g.24179G>A	splicing defect	CYP2C19	rs4244285	94781859
777519	91	19239G>A	g.94781944G>A	g.24264G>A	p.D256N	CYP2C19	rs375781227	94781944
777520	91	19294T>A	g.94781999T>A	g.24319T>A	splicing defect	CYP2C19	rs72558186	94781999
777521	91	80156G>A	g.94842861G>A	g.85181G>A	p.R329H	CYP2C19	rs138142612	94842861
777522	91	80161A>G	g.94842866A>G	g.85186A>G	p.I331V	CYP2C19	rs3758581	94842866
777523	91	80174G>A	g.94842879G>A	g.85199G>A	p.R335Q	CYP2C19	rs118203757	94842879
777524	91	80290G>A	g.94842995G>A	g.85315G>A	p.V374I	CYP2C19	rs113934938	94842995
777525	91	87290C>T	g.94849995C>T	g.92315C>T	p.R410C	CYP2C19	rs17879685	94849995
777526	91	90033C>T	g.94852738C>T	g.95058C>T	p.R433W	CYP2C19	rs56337013	94852738
777527	91	90060C>T	g.94852765C>T	g.95085C>T	p.R442C	CYP2C19	rs192154563	94852765
777528	91	90080C>G	g.94852785C>G	g.95105C>G	p.F448L	CYP2C19	rs118203759	94852785
6235852	1	18726C>G	g.15878886G>C	g.24189C>G	p.A483G	CYP4F2	rs3952537	15878886
6235855	1	18199C>T	g.15879413G>A	g.23662C>T	p.R444C	CYP4F2	rs142113670	15879413
6235860	1	5233C>T	g.15892379G>A	g.10696C>T	p.T152M	CYP4F2	rs200629062	15892379
6235861	1	5214C>T	g.15892398G>A	g.10677C>T	p.R146C	CYP4F2	rs556151888	15892398
777282	91	S549R(A>C)	g.117587799A>C	g.127016A>C	p.S549R	CFTR	rs121908757	117587799
777283	91	S549R(T>G)	g.117587801T>G	g.127018T>G	p.S549R	CFTR	rs121909005	117587801
777498	91	7C>T	g.94762712C>T	g.5032C>T	p.P3S	CYP2C19	rs367543002	94762712
777499	91	10T>C	g.94762715T>C	g.5035T>C	p.F4L	CYP2C19	rs367543003	94762715
6235863	1	2086G>A	g.15895526C>T	g.7549G>A	p.R108Q	CYP4F2	rs148396222	15895526
6235865	1	2061A>G	g.15895551T>C	g.7524A>G	p.S100G	CYP4F2	rs150579280	15895551
778508	91	c.179T>C	g.154536025A>G	g.16548T>C	p.L60P	G6PD	\N	154536025
2406797	53	c.383T>G;c.383T>C	g.154535270A>C;g.154535270A>G	g.17303T>G;g.17303T>C	p.L128R;p.L128P	G6PD	rs78365220	154535270
779272	91	97539A>G	g.21239113A>G	g.112920A>G	p.E667G	SLCO1B1	rs55737008	21239113
777497	91	1A>G	g.94762706A>G	g.5026A>G	p.M1V	CYP2C19	rs28399504	94762706
777529	91	90209A>C	g.94852914A>C	g.95234A>C	p.X491C	CYP2C19	rs55640102	94852914
777604	91	89C>T	g.94938771C>T	g.5614C>T	p.P30L	CYP2C9	rs142240658	94938771
777618	91	3552G>A; 3552G>T	g.94942234G>A; g.94942234G>T	g.9077G>A; g.9077G>T	p.R125H; p.R125L	CYP2C9	rs72558189	94942234
777647	91	42548C>A	g.94981230C>A	g.48073C>A	p.P337T	CYP2C9	rs1274535931	94981230
777667	91	50341G>T	g.94989023G>T	g.55866G>T	p.V490F	CYP2C9	rs868182778	94989023
778312	91	c.2623A>C	g.97098632T>G	g.827428A>C	p.K875Q	DPYD	rs201035051	97098632
778313	91	c.2639G>T	g.97098616C>A	g.827444G>T	p.G880V	DPYD	rs55674432	97098616
778314	91	c.2656C>T	g.97098599G>A	g.827461C>T	p.R886C	DPYD	rs147545709	97098599
778315	91	c.2657G>A	g.97098598C>T	g.827462G>A	p.R886H	DPYD	rs1801267	97098598
778324	91	c.3049G>A	g.97079005C>T	g.847055G>A	p.V1017I	DPYD	rs140114515	97079005
778325	91	c.3061G>C	g.97078993C>G	g.847067G>C	p.V1021L	DPYD	rs148799944	97078993
779045	91	2T>C	g.48037748T>C	g.5182T>C	p.M1T	NUDT15	rs769369441	48037748
779046	91	3G>C	g.48037749G>C	g.5183G>C	p.M1I	NUDT15	\N	48037749
779048	91	52G>A	g.48037798G>A	g.5232G>A	p.V18I	NUDT15	rs186364861	48037798
779050	91	80_81insCGGG	g.48037826_48037827insCGGG	g.5260_5261insCGGG	p.C28fs	NUDT15	rs777311140	48037826
779051	91	88C>T	g.48037834C>T	g.5268C>T	p.L30V	NUDT15	rs1202487323	48037834
779273	91	97571C>T	g.21239145C>T	g.112952C>T	p.H678Y	SLCO1B1	rs200995543	21239145
779274	91	97584C>T	g.21239158C>T	g.112965C>T	p.S682F	SLCO1B1	rs140790673	21239158
779052	91	101G>C	g.48037847G>C	g.5281G>C	p.R34T	NUDT15	rs766023281	48037847
779053	91	103A>G	g.48037849A>G	g.5283A>G	p.K35E	NUDT15	\N	48037849
779054	91	139G>A	g.48037885G>A	g.5319G>A	p.G47R	NUDT15	rs1950545307	48037885
779055	91	156C>G	g.48037902C>G	g.5336C>G	p.F52L	NUDT15	rs149436418	48037902
949537	83	3236delA	g.48040982del	g.8416del	p.N74fs	NUDT15	rs1457579126	48040982
949538	83	3358_3359insG	g.48041104dup	g.8538dup	p.E115fs	NUDT15	rs761191455	48041104
779058	91	3367G>T	g.48041113G>T	g.8547G>T	p.E118X	NUDT15	rs1368252918	48041113
779059	91	7944C>G	g.48045690C>G	g.13124C>G	p.P129R	NUDT15	rs768324690	48045690
5881932	4	7968G>C	g.48045714G>C	g.13148G>C	p.G137A	NUDT15	rs1185228044	48045714
779060	91	7973C>T	g.48045719C>T	g.13153C>T	p.R139C	NUDT15	rs116855232	48045719
6237858	1	37079C>G	g.21178653C>G	g.52460C>G	p.P187A	SLCO1B1	rs200331427	21178653
6237859	1	37352A>G	g.21178926A>G	g.52733A>G	p.I211M	SLCO1B1	rs201722521	21178926
6237866	1	59099G>A	g.21200673G>A	g.74480G>A	splicing defect	SLCO1B1	rs756393362	21200673
1002617	81	80781C>T	g.21222355C>T	g.96162C>T	p.R580X	SLCO1B1	rs71581941	21222355
6237875	1	83266G>A	g.21224840G>A	g.98647G>A	splicing defect	SLCO1B1	rs200994482	21224840
779270	91	97468A>C	g.21239042A>C	g.112849A>C	p.L643F	SLCO1B1	rs34671512	21239042
779271	91	97503A>G	g.21239077A>G	g.112884A>G	p.D655G	SLCO1B1	rs56199088	21239077
777419	91	25500A>T	g.41016805A>T	g.30507A>T	p.Q485L	CYP2B6	rs2516199080	41016805
777614	91	3534A>G	g.94942216A>G	g.9059A>G	p.K119R	CYP2C9	rs774607211	94942216
777615	91	3548C>T	g.94942230C>T	g.9073C>T	p.R124W	CYP2C9	rs767576260	94942230
777616	91	3549G>A	g.94942231G>A	g.9074G>A	p.R124Q	CYP2C9	rs12414460	94942231
777617	91	3551C>T	g.94942233C>T	g.9076C>T	p.R125C	CYP2C9	rs375805362	94942233
1932776	62	3561T>G	g.94942243T>G	g.9086T>G	p.L128R	CYP2C9	rs1375956433	94942243
777619	91	3567C>G; 3567C>T	g.94942249C>G; g.94942249C>T	g.9092C>G; g.9092C>T	p.T130R; p.T130M	CYP2C9	rs200965026	94942249
777620	91	3572C>T	g.94942254C>T	g.9097C>T	p.R132W	CYP2C9	rs199523631	94942254
777621	91	3573G>A	g.94942255G>A	g.9098G>A	p.R132Q	CYP2C9	rs200183364	94942255
777622	91	3608C>T	g.94942290C>T	g.9133C>T	p.R144C	CYP2C9	rs1799853	94942290
777623	91	3609G>A	g.94942291G>A	g.9134G>A	p.R144H	CYP2C9	rs141489852	94942291
777624	91	3623G>A	g.94942305G>A	g.9148G>A	p.A149T	CYP2C9	rs754487195	94942305
1406126	73	3624C>T	g.94942306C>T	g.9149C>T	p.A149V	CYP2C9	rs1289704600	94942306
777832	91	1022C>A; 1022C>T	g.42129770G>T; g.42129770G>A	g.6041C>A; g.6041C>T	p.T107N; p.T107I	CYP2D6	rs28371706	42129770
777607	91	3215G>C	g.94941897G>C	g.8740G>C	p.G70R	CYP2C9	rs371055887	94941897
2406876	53	c.1089C>G;c.1089C>A	g.154532765G>C;g.154532765G>T	g.19808C>G;g.19808C>A	p.N363K;N363K	G6PD	rs137852329	154532765
777602	91	1A>G	g.94938683A>G	g.5526A>G	p.M1V	CYP2C9	rs114071557	94938683
1932756	62	37T>G	g.94938719T>G	g.5562T>G	p.C13G	CYP2C9	\N	94938719
777603	91	55C>A	g.94938737C>A	g.5580C>A	p.L19I	CYP2C9	rs67807361	94938737
1932759	62	106C>T	g.94938788C>T	g.5631C>T	p.L36F	CYP2C9	\N	94938788
777608	91	3233G>A	g.94941915G>A	g.8758G>A	p.V76M	CYP2C9	rs1216169538	94941915
777609	91	3276T>C	g.94941958T>C	g.8801T>C	p.L90P	CYP2C9	rs72558187	94941958
1932766	62	3293G>A	g.94941975G>A	g.8818G>A	p.G96R	CYP2C9	rs2493006942	94941975
777610	91	3294G>C	g.94941976G>C	g.8819G>C	p.G96A	CYP2C9	rs761033063	94941976
777611	91	3300G>T	g.94941982G>T	g.8825G>T	p.G98V	CYP2C9	rs762239445	94941982
1406127	73	3626C>T	g.94942308C>T	g.9151C>T	p.R150C	CYP2C9	rs17847037	94942308
777625	91	3627G>A; 3627G>T	g.94942309G>A; g.94942309G>T	g.9152G>A; g.9152G>T	p.R150H; p.R150L	CYP2C9	rs7900194	94942309
777626	91	9100C>A	g.94947782C>A	g.14625C>A	p.S162X	CYP2C9	rs72558190	94947782
777627	91	9103C>T	g.94947785C>T	g.14628C>T	p.P163L	CYP2C9	rs774550549	94947785
777628	91	9187A>G	g.94947869A>G	g.14712A>G	p.D191G	CYP2C9	rs2492587526	94947869
777629	91	9225A>C	g.94947907A>C	g.14750A>C	p.N204H	CYP2C9	\N	94947907
777630	91	9235T>C	g.94947917T>C	g.14760T>C	p.I207T	CYP2C9	rs1326630788	94947917
777631	91	9256A>T	g.94947938A>T	g.14781A>T	p.Q214L	CYP2C9	rs2031531005	94947938
1985225	61	9257G>T	g.94947939G>T	g.14782G>T	p.Q214H	CYP2C9	rs370100007	94947939
777632	91	10447A>G	g.94949129A>G	g.15972A>G	p.I222V	CYP2C9	\N	94949129
777633	91	10462C>T	g.94949144C>T	g.15987C>T	p.P227S	CYP2C9	rs2492591692	94949144
1932795	62	10463C>T	g.94949145C>T	g.15988C>T	p.P227L	CYP2C9	rs772782449	94949145
1932796	62	10481delT	g.94949163del	g.16006del	p.L233fs	CYP2C9	\N	94949163
777634	91	10535A>G	g.94949217A>G	g.16060A>G	p.H251R	CYP2C9	rs2256871	94949217
777635	91	10598A>G	g.94949280A>G	g.16123A>G	p.E272G	CYP2C9	rs9332130	94949280
948046	83	10601delA	g.94949283del	g.16126del	p.K273fs	CYP2C9	rs9332131	94949283
777637	91	33437C>A	g.94972119C>A	g.38962C>A	p.P279T	CYP2C9	rs182132442	94972119
777638	91	33441C>G	g.94972123C>G	g.38966C>G	p.S280C	CYP2C9	\N	94972123
777639	91	33452A>G	g.94972134A>G	g.38977A>G	p.I284V	CYP2C9	rs2492634549	94972134
777640	91	33497A>G	g.94972179A>G	g.39022A>G	p.T299A	CYP2C9	rs72558192	94972179
777641	91	33498C>G	g.94972180C>G	g.39023C>G	p.T299R	CYP2C9	rs988617574	94972180
777661	91	50198G>T	g.94988880G>T	g.55723G>T	p.G442V	CYP2C9	rs2492662839	94988880
777923	91	4132A>G	g.42126660T>C	g.9151A>G	p.T470A	CYP2D6	rs1135835	42126660
3307484	36	3261_3262insTG	g.42127532_42127533dup	g.8279_8280dup	p.Q364fs	CYP2D6	rs72549346	42127532
1103041	79	2590delCTGA	g.42128199TCAG[1]	g.7605CTGA[1]	p.T272fs	CYP2D6	rs72549351	42128199
777856	91	1888_1889insTA	g.42128903_42128904insTA	g.6907_6908insTA	p.S183X	CYP2D6	\N	42128903
1355509	74	1864_1865insTTTCGCCCCTTTCGCCCC; 1864_1865insTTTCGCCCC	g.42128934AAAGGGGCG[3]; g.42128934_42128942dup	g.6875TTTCGCCCC[3]; g.6875_6883dup	p.174_175insFRPx2; p.174_175insFRP	CYP2D6	rs72549356	42128934
778595	91	c.1000_1002delACC	g.154532991_154532993delGGT	g.19580_19582delACC	p.T334del	G6PD	\N	154532991
778596	91	c.1003G>A	g.154532990C>T	g.19583G>A	p.A335T	G6PD	rs5030869	154532990
778597	91	c.1004C>A	g.154532989G>T	g.19584C>A	p.A335D	G6PD	\N	154532989
778606	91	c.1084_1101delCTGAACGAGCGCAAGGCC	g.154532753_154532770delGGCCTTGCGCTCGTTCAG	g.19803_19820delCTGAACGAGCGCAAGGCC	p.L362_A367del	G6PD	\N	154532753
1932760	62	118G>A	g.94938800G>A	g.5643G>A	p.G40R	CYP2C9	rs1364419386	94938800
777605	91	121A>G	g.94938803A>G	g.5646A>G	p.N41D	CYP2C9	rs2031308986	94938803
777606	91	146A>G	g.94938828A>G	g.5671A>G	p.D49G	CYP2C9	rs564813580	94938828
777612	91	3336T>C	g.94942018T>C	g.8861T>C	p.F110S	CYP2C9	\N	94942018
777660	91	50173A>T	g.94988855A>T	g.55698A>T	p.I434F	CYP2C9	rs2492662738	94988855
777662	91	50235G>C	g.94988917G>C	g.55760G>C	p.Q454H	CYP2C9	rs769942899	94988917
777663	91	50243A>G	g.94988925A>G	g.55768A>G	p.N457S	CYP2C9	rs202201137	94988925
777664	91	50273T>C	g.94988955T>C	g.55798T>C	p.L467P	CYP2C9	rs767284820	94988955
777665	91	50302G>A	g.94988984G>A	g.55827G>A	p.A477T	CYP2C9	rs781583846	94988984
779104	91	c.103T>C	g.38440802T>C	g.12103T>C	p.C35R	RYR1	rs193922747	38440802
3684994	29	c.119G>C	g.38440818G>C	g.12119G>C	p.G40A	RYR1	\N	38440818
779105	91	c.130C>T	g.38440829C>T	g.12130C>T	p.R44C	RYR1	rs193922748	38440829
3684996	29	c.131G>A	g.38440830G>A	g.12131G>A	p.R44H	RYR1	rs139161723	38440830
3684997	29	c.152C>A	g.38440851C>A	g.12152C>A	p.T51N	RYR1	rs193922749	38440851
3684998	29	c.178G>A; c.178G>T	g.38442361G>A; g.38442361G>T	g.13662G>A; g.13662G>T	p.D60N; p.D60Y	RYR1	rs118192160	38442361
3684999	29	c.190T>C	g.38442373T>C	g.13674T>C	p.C64R	RYR1	rs995399438	38442373
3685000	29	c.212C>A	g.38442395C>A	g.13696C>A	p.S71Y	RYR1	rs118192113	38442395
3685005	29	c.467G>A	g.38444191G>A	g.15492G>A	p.R156K	RYR1	rs193922751	38444191
3685006	29	c.479A>G	g.38444203A>G	g.15504A>G	p.E160G	RYR1	rs193922752	38444203
777642	91	33551C>T	g.94972233C>T	g.39076C>T	p.P317S	CYP2C9	rs1237225311	94972233
777643	91	42517G>T	g.94981199G>T	g.48042G>T	p.E326D	CYP2C9	\N	94981199
777644	91	42519T>C	g.94981201T>C	g.48044T>C	p.I327T	CYP2C9	rs57505750	94981201
777645	91	42542C>T	g.94981224C>T	g.48067C>T	p.R335W	CYP2C9	rs28371685	94981224
777646	91	42543G>A	g.94981225G>A	g.48068G>A	p.R335Q	CYP2C9	rs367826293	94981225
777666	91	50338C>T	g.94989020C>T	g.55863C>T	p.P489S	CYP2C9	rs9332239	94989020
3685001	29	c.251C>T	g.38442434C>T	g.13735C>T	p.T84M	RYR1	rs186983396	38442434
3685002	29	c.418G>A	g.38443790G>A	g.15091G>A	p.A140T	RYR1	rs142474192	38443790
3685003	29	c.455C>A	g.38444179C>A	g.15480C>A	p.A152D	RYR1	\N	38444179
3685004	29	c.463C>A	g.38444187C>A	g.15488C>A	p.Q155K	RYR1	rs193922750	38444187
779106	91	c.487C>T	g.38444211C>T	g.15512C>T	p.R163C	RYR1	rs118192161	38444211
3685009	29	c.493G>A	g.38444217G>A	g.15518G>A	p.G165R	RYR1	rs193922754	38444217
3685010	29	c.496G>A	g.38444220G>A	g.15521G>A	p.D166N	RYR1	rs193922755	38444220
3685011	29	c.497A>G	g.38444221A>G	g.15522A>G	p.D166G	RYR1	rs193922756	38444221
3685012	29	c.526G>A	g.38444250G>A	g.15551G>A	p.E176K	RYR1	rs761616815	38444250
3685013	29	c.528G>T	g.38444252G>T	g.15553G>T	p.E176D	RYR1	\N	38444252
779109	91	c.982C>T	g.38448673C>T	g.19974C>T	p.R328W	RYR1	rs193922762	38448673
779110	91	c.1021G>A; c.1021G>C	g.38448712G>A; g.38448712G>C	g.20013G>A; g.20013G>C	p.G341R; p.G341R	RYR1	rs121918592	38448712
779137	91	c.7522C>T; c.7522C>G	g.38500898C>T; g.38500898C>G	g.72199C>T; g.72199C>G	p.R2508C; p.R2508G	RYR1	rs118192178	38500898
779138	91	c.7523G>A	g.38500899G>A	g.72200G>A	p.R2508H	RYR1	rs193922818	38500899
3685151	29	c.7355G>A; c.7355G>C	g.38500637G>A; g.38500637G>C	g.71938G>A; g.71938G>C	p.R2452Q; p.R2452P	RYR1	rs193922815	38500637
3685158	29	c.7487C>T	g.38500863C>T	g.72164C>T	p.P2496L	RYR1	rs193922817	38500863
3685161	29	c.7528T>C	g.38500904T>C	g.72205T>C	p.Y2510H	RYR1	rs193922819	38500904
3685185	29	c.9152G>A	g.38511590G>A	g.82891G>A	p.R3051H	RYR1	rs147303895	38511590
3685297	29	c.14817C>A	g.38585951C>A	g.157252C>A	p.D4939E	RYR1	rs193922895	38585951
3685298	29	c.14818G>A	g.38585952G>A	g.157253G>A	p.A4940T	RYR1	rs118192158	38585952
1932805	62	33501A>T	g.94972183A>T	g.39026A>T	p.E300V	CYP2C9	\N	94972183
777655	91	42683C>T	g.94981365C>T	g.48208C>T	p.P382S	CYP2C9	rs2492650213	94981365
777656	91	42689G>A	g.94981371G>A	g.48214G>A	splicing defect	CYP2C9	rs542577750	94981371
777657	91	47360A>G	g.94986042A>G	g.52885A>G	p.I387V	CYP2C9	rs764211126	94986042
777658	91	47391A>C	g.94986073A>C	g.52916A>C	p.D397A	CYP2C9	rs72558193	94986073
1406163	73	47454A>C	g.94986136A>C	g.52979A>C	p.N418T	CYP2C9	rs1254213342	94986136
1932825	62	47492G>C	g.94986174G>C	g.53017G>C	p.G431R	CYP2C9	rs1441296358	94986174
777659	91	50170C>T	g.94988852C>T	g.55695C>T	p.R433W	CYP2C9	rs776908257	94988852
777925	91	4145G>A	g.42126647C>T	g.9164G>A	p.R474Q	CYP2D6	rs141756339	42126647
4058570	21	18692A>G	g.15878920T>C	g.24155A>G	p.T472A	CYP4F2	rs4020346	15878920
2784563	46	7207G>T	g.15890405C>A	g.12670G>T	p.G185V	CYP4F2	rs3093153	15890405
3684990	29	c.38T>G	g.38433867T>G	g.5168T>G	p.L13R	RYR1	rs193922744	38433867
3684991	29	c.51_53del	g.38440750_38440752delTGA	g.12051_12053delTGA	p.D17del	RYR1	rs193922745	38440750
3684992	29	c.97A>G	g.38440796A>G	g.12097A>G	p.K33E	RYR1	rs193922746	38440796
2090878	59	2452C>T	g.42128340G>A	g.7471C>T	p.A226V	CYP2D6	rs140900383	42128340
777863	91	2441G>A	g.42128351C>T	g.7460G>A	splicing defect	CYP2D6	rs377725912	42128351
1103029	79	1996delC	g.42128796del	g.7015del	p.L220fs	CYP2D6	\N	42128796
2090875	59	1985G>A	g.42128807C>T	g.7004G>A	p.E215K	CYP2D6	rs567606867	42128807
777861	91	1980T>C	g.42128812A>G	g.6999T>C	p.L213P	CYP2D6	rs199535154	42128812
1609173	69	1979C>T	g.42128813G>A	g.6998C>T	\N	CYP2D6	rs150163869	42128813
1103027	79	1977_1978insG	g.42128817dup	g.6996dup	p.L213fs	CYP2D6	rs72549354	42128817
778281	91	c.1403C>A	g.97549681G>T	g.376379C>A	p.T468N	DPYD	rs199549923	97549681
778309	91	c.2336C>A	g.97234958G>T	g.691102C>A	p.T779N	DPYD	rs199634007	97234958
778512	91	c.202G>A	g.154536002C>T	g.16571G>A	p.V68M	G6PD	rs1050828	154536002
3685100	29	c.6544A>T	g.38494621A>T	g.65922A>T	p.I2182F	RYR1	rs193922790	38494621
2676652	48	2465delCCT	g.42128326GGA[1]	g.7481CCT[1]	p.L231del	CYP2D6	rs777691989	42128326
777864	91	2463C>T	g.42128329G>A	g.7482C>T	p.L230F	CYP2D6	rs373813287	42128329
2676644	48	1973_1974insG	g.42128820dup	g.6992dup	p.E211fs	CYP2D6	rs763609904	42128820
777859	91	1944G>A	g.42128848C>T	g.6963G>A	p.R201H	CYP2D6	rs745365204	42128848
2676642	48	1928G>A	g.42128864C>T	g.6947G>A	p.E196K	CYP2D6	rs755518310	42128864
2676638	48	1866A>G	g.42128926T>C	g.6885A>G	p.N175S	CYP2D6	rs1459127426	42128926
2676637	48	1860G>A	g.42128932C>T	g.6879G>A	p.R173H	CYP2D6	rs556882139	42128932
777854	91	1847G>A	g.42128945C>T	g.6866G>A	splicing defect	CYP2D6	rs3892097	42128945
3619338	30	1759G>T; 1759G>A	g.42129033C>A; g.42129033C>T	g.6778G>T; g.6778G>A	p.G169X; p.G169R	CYP2D6	rs5030865	42129033
777852	91	1756T>G	g.42129036A>C	g.6775T>G	p.S168A	CYP2D6	rs1135826	42129036
777851	91	1755C>A	g.42129037G>T	g.6774C>A	p.H167Q	CYP2D6	rs1135825	42129037
777850	91	1750A>G	g.42129042T>C	g.6769A>G	p.N166D	CYP2D6	rs1135824	42129042
2090861	59	1748C>T	g.42129044G>A	g.6767C>T	p.A165V	CYP2D6	rs201006451	42129044
777849	91	1736G>C	g.42129056C>G	g.6755G>C	p.C161S	CYP2D6	rs774943042	42129056
777848	91	1721A>C; 1721A>T	g.42129071T>G; g.42129071T>A	g.6740A>C; g.6740A>T	p.E156A; p.E156V	CYP2D6	rs267608302	42129071
777847	91	1717G>A	g.42129075C>T	g.6736G>A	p.E155K	CYP2D6	rs28371710	42129075
1103013	79	1708delT	g.42129084del	g.6727del	p.W152fs	CYP2D6	rs5030655	42129084
777845	91	1705C>G	g.42129087G>C	g.6724C>G	p.Q151E	CYP2D6	rs78482768	42129087
777844	91	1694A>G	g.42129098T>C	g.6713A>G	p.K147R	CYP2D6	rs569229126	42129098
777843	91	1679T>C	g.42129113A>G	g.6698T>C	p.L142S	CYP2D6	rs375135093	42129113
777842	91	1662G>C	g.42129130C>G	g.6681G>C	\N	CYP2D6	rs1058164	42129130
777841	91	1660G>A	g.42129132C>T	g.6679G>A	p.V136M	CYP2D6	rs61736512	42129132
777840	91	1658C>T	g.42129134G>A	g.6677C>T	p.S135F	CYP2D6	rs781457579	42129134
777839	91	1637G>A	g.42129155C>T	g.6656G>A	p.W128X	CYP2D6	rs1180015037	42129155
2090849	59	1636T>C	g.42129156A>G	g.6655T>C	p.W128R	CYP2D6	rs376636053	42129156
777838	91	1626T>G	g.42129166A>C	g.6645T>G	p.Y124X	CYP2D6	rs766391487	42129166
777837	91	1618G>T	g.42129174C>A	g.6637G>T	p.A122S	CYP2D6	rs1135823	42129174
777836	91	1612T>A	g.42129180A>T	g.6631T>A	p.F120I	CYP2D6	rs1135822	42129180
2090845	59	1609G>A; 1609G>T	g.42129183C>T; g.42129183C>A	g.6628G>A; g.6628G>T	p.V119M; p.V119L	CYP2D6	rs374616348	42129183
2676613	48	1052A>G	g.42129740T>C	g.6071A>G	p.Q117R	CYP2D6	\N	42129740
3318096	35	1039G>C	g.42129753C>G	g.6058G>C	p.G113R	CYP2D6	rs563185985	42129753
777834	91	1033G>A	g.42129759C>T	g.6052G>A	p.G111S	CYP2D6	rs535642512	42129759
777833	91	1027A>G	g.42129765T>C	g.6046A>G	p.I109V	CYP2D6	rs78459009	42129765
777831	91	1021A>T	g.42129771T>A	g.6040A>T	p.T107S	CYP2D6	rs74802369	42129771
777830	91	1013T>C	g.42129779A>G	g.6032T>C	p.V104A	CYP2D6	rs76187628	42129779
777829	91	1012G>A	g.42129780C>T	g.6031G>A	p.V104M	CYP2D6	rs267608308	42129780
1102995	79	993C>G	g.42129799G>C	g.6012C>G	p.D97E	CYP2D6	rs76802407	42129799
777828	91	983A>G	g.42129809T>C	g.6002A>G	p.H94R	CYP2D6	rs28371704	42129809
777827	91	973C>A	g.42129819G>T	g.5992C>A	p.L91M	CYP2D6	rs28371703	42129819
777826	91	971C>T	g.42129821G>A	g.5990C>T	p.A90V	CYP2D6	rs267608309	42129821
777825	91	965G>C	g.42129827C>G	g.5984G>C	p.R88P	CYP2D6	rs267608276	42129827
777824	91	956C>T	g.42129836G>A	g.5975C>T	p.A85V	CYP2D6	rs267608310	42129836
777823	91	905T>G	g.42129887A>C	g.5924T>G	p.V68G	CYP2D6	rs1456026511	42129887
777821	91	882G>C	g.42129910C>G	g.5901G>C	splicing defect	CYP2D6	rs201377835	42129910
2090829	59	154C>T	g.42130638G>A	g.5173C>T	p.Q52X	CYP2D6	rs536109057	42130638
1102986	79	137_138insT	g.42130655dup	g.5156dup	p.L47fs	CYP2D6	rs774671100	42130655
777819	91	125G>A	g.42130667C>T	g.5144G>A	p.G42E	CYP2D6	rs118203758	42130667
777818	91	124G>A	g.42130668C>T	g.5143G>A	p.G42R	CYP2D6	rs5030862	42130668
2090825	59	122C>T	g.42130670G>A	g.5141C>T	p.P41L	CYP2D6	rs373243894	42130670
777817	91	100C>T	g.42130692G>A	g.5119C>T	p.P34S	CYP2D6	rs1065852	42130692
777816	91	82C>T	g.42130710G>A	g.5101C>T	p.R28C	CYP2D6	rs138100349	42130710
777815	91	77G>A	g.42130715C>T	g.5096G>A	p.R26H	CYP2D6	rs28371696	42130715
777814	91	73C>T	g.42130719G>A	g.5092C>T	p.R25W	CYP2D6	rs267608313	42130719
1102979	79	64delC	g.42130729del	g.5083del	p.L22X	CYP2D6	\N	42130729
777812	91	31G>A	g.42130761C>T	g.5050G>A	p.V11M	CYP2D6	rs769258	42130761
777811	91	19G>A	g.42130773C>T	g.5038G>A	p.V7M	CYP2D6	rs72549358	42130773
777810	91	14C>T	g.42130778G>A	g.5033C>T	p.A5V	CYP2D6	rs773790593	42130778
948658	83	c.299_302del	g.97740411ATGA[1]	g.185642TCAT[1]	\N	DPYD	rs72549309	97740411
778275	91	c.1278G>T	g.97573821C>A	g.352239G>T	p.M426I	DPYD	rs764666241	97573821
778277	91	c.1314T>G	g.97573785A>C	g.352275T>G	p.F438L	DPYD	rs186169810	97573785
777882	91	2870T>C	g.42127922A>G	g.7889T>C	p.L302P	CYP2D6	rs1406719554	42127922
777881	91	2854A>C	g.42127938T>G	g.7873A>C	p.I297L	CYP2D6	rs949717872	42127938
777880	91	2851C>T	g.42127941G>A	g.7870C>T	p.R296C	CYP2D6	rs16947	42127941
1103046	79	2829delC	g.42127963del	g.7848del	p.S288fs	CYP2D6	rs267608279	42127963
777878	91	2819A>G	g.42127973T>C	g.7838A>G	p.N285S	CYP2D6	rs1135829	42127973
1103044	79	2616delAAG	g.42128176_42128178del	g.7635_7637del	p.K281del	CYP2D6	rs5030656	42128176
777876	91	2611T>A	g.42128181A>T	g.7630T>A	p.M279K	CYP2D6	rs1135828	42128181
777875	91	2607G>A	g.42128185C>T	g.7626G>A	p.E278K	CYP2D6	rs77913725	42128185
2090890	59	2591_2592insT	g.42128201dup	g.7610dup	p.E273X	CYP2D6	rs368858603	42128201
777872	91	2580C>T	g.42128212G>A	g.7599C>T	p.R269X	CYP2D6	rs367543000	42128212
777870	91	2557C>T	g.42128235G>A	g.7576C>T	p.T261I	CYP2D6	rs267608297	42128235
1103036	79	2550delA	g.42128242del	g.7569del	p.R259fs	CYP2D6	rs35742686	42128242
1103035	79	2540delAACT	g.42128251_42128254del	g.7559_7562del	p.T256fs	CYP2D6	rs72549353	42128251
777867	91	2520A>C	g.42128272T>G	g.7539A>C	p.T249P	CYP2D6	\N	42128272
777866	91	2484G>T	g.42128308C>A	g.7503G>T	p.A237S	CYP2D6	rs28371717	42128308
777865	91	2467T>C	g.42128325A>G	g.7486T>C	p.L231P	CYP2D6	rs17002853	42128325
2406779	53	c.185C>T;c.185C>A	g.154536019G>A;g.154536019G>T	g.16554C>T;g.16554C>A	p.P62L;p.P62H	G6PD	\N	154536019
777904	91	3280G>A	g.42127512C>T	g.8299G>A	p.V370I	CYP2D6	rs61745683	42127512
777903	91	3278T>C	g.42127514A>G	g.8297T>C	p.I369T	CYP2D6	rs1555888899	42127514
777893	91	3184G>A	g.42127608C>T	g.8203G>A	p.V338M	CYP2D6	rs59421388	42127608
777892	91	3182A>G	g.42127610T>C	g.8201A>G	p.D337G	CYP2D6	rs748712690	42127610
777891	91	3181G>A	g.42127611C>T	g.8200G>A	p.D337N	CYP2D6	rs78209835	42127611
777890	91	3173A>C	g.42127619T>G	g.8192A>C	p.E334A	CYP2D6	rs72549348	42127619
777889	91	3161G>C	g.42127631C>G	g.8180G>C	p.R330P	CYP2D6	rs141009491	42127631
777888	91	2989G>A	g.42127803C>T	g.8008G>A	splicing defect	CYP2D6	rs28371725	42127803
777887	91	2951G>C	g.42127841C>G	g.7970G>C	splicing defect	CYP2D6	rs72549349	42127841
1103051	79	2928delGATCCTACATCCGGATGTG	g.42127846_42127864del	g.7947_7965del	p.M321fs	CYP2D6	rs730882170	42127846
777886	91	2940G>A	g.42127852C>T	g.7959G>A	splicing defect	CYP2D6	rs79292917	42127852
777885	91	2936A>C	g.42127856T>G	g.7955A>C	p.H324P	CYP2D6	rs5030867	42127856
777883	91	2893A>G	g.42127899T>C	g.7912A>G	p.T310A	CYP2D6	\N	42127899
777871	91	2575C>A	g.42128217G>T	g.7594C>A	p.P267H	CYP2D6	rs148769737	42128217
778539	91	c.487G>A	g.154534495C>T	g.18078G>A	p.G163S	G6PD	rs137852314	154534495
778551	91	c.561_563delCTC	g.154534419_154534421delGAG	g.18152_18154delCTC	p.S188del	G6PD	\N	154534419
778589	91	c.955_988delACCAAAGGGTACCTGGACGACCCC	g.154533015_154533038delGGGGTCGTCCAGGTACCCTTTGGT	g.19535_19569delACCAAAGGGTACCTGGACGACCCC	p.T319_P326del	G6PD	\N	154533015
778614	91	c.1154G>T	g.154532700C>A	g.19873G>T	p.C385F	G6PD	\N	154532700
778624	91	c.1180G>C	g.154532674C>G	g.19899G>C	p.V394L	G6PD	rs137852335	154532674
778625	91	c.1187C>T	g.154532667G>A	g.19906C>T	p.P396L	G6PD	\N	154532667
778626	91	c.1192G>A	g.154532662C>T	g.19911G>A	p.E398K	G6PD	rs137852325	154532662
778627	91	c.1193A>G	g.154532661T>C	g.19912A>G	p.E398G	G6PD	\N	154532661
778628	91	c.1205C>A	g.154532649G>T	g.19924C>A	p.T402N	G6PD	\N	154532649
778629	91	c.1215G>A	g.154532639C>T	g.19934G>A	p.M405I	G6PD	\N	154532639
778630	91	c.1220A>C	g.154532634T>G	g.19939A>C	p.K407T	G6PD	\N	154532634
778631	91	c.1225C>T	g.154532629G>A	g.19944C>T	p.P409S	G6PD	\N	154532629
778633	91	c.1228G>T	g.154532626C>A	g.19947G>T	p.G410C	G6PD	rs137852323	154532626
2406921	53	c.1376G>T;c.1376G>C	g.154532269C>A;g.154532269C>G	g.20304G>T;g.20304G>C	p.R459L;p.R459P	G6PD	rs72554665	154532269
779378	91	514T>C	g.18133870A>G	g.26274T>C	p.S172P	TPMT	rs772832951	18133870
779379	91	537G>T	g.18133847C>A	g.26297G>T	p.Q179H	TPMT	rs6921269	18133847
777902	91	3269T>C	g.42127523A>G	g.8288T>C	p.F366S	CYP2D6	rs1555888910	42127523
777901	91	3266G>A	g.42127526C>T	g.8285G>A	p.R365H	CYP2D6	rs1058172	42127526
777899	91	3236A>G	g.42127556T>C	g.8255A>G	p.Y355C	CYP2D6	rs202102799	42127556
777898	91	3227A>G	g.42127565T>C	g.8246A>G	p.H352R	CYP2D6	rs61736517	42127565
777897	91	3203G>A	g.42127589C>T	g.8222G>A	p.R344Q	CYP2D6	rs76088846	42127589
777896	91	3202C>T	g.42127590G>A	g.8221C>T	p.R344X	CYP2D6	rs72549347	42127590
777894	91	3190G>A	g.42127602C>T	g.8209G>A	p.G340R	CYP2D6	rs566108360	42127602
2090910	59	3187A>C	g.42127605T>G	g.8206A>C	p.I339L	CYP2D6	rs141824015	42127605
1103040	79	2580_2581insC	g.42128218dup	g.7599dup	p.R269fs	CYP2D6	rs72549352	42128218
777934	91	4187C>T	g.42126605G>A	g.9206C>T	p.S488F	CYP2D6	rs568495591	42126605
777922	91	4129C>G	g.42126663G>C	g.9148C>G	p.P469A	CYP2D6	rs1135833	42126663
777920	91	4095C>A	g.42126697G>T	g.9114C>A	p.F457L	CYP2D6	\N	42126697
2090937	59	4077G>A	g.42126715C>T	g.9096G>A	p.M451I	CYP2D6	rs760940331	42126715
777919	91	4073G>A	g.42126719C>T	g.9092G>A	p.R450H	CYP2D6	rs369177208	42126719
777918	91	4057G>A	g.42126735C>T	g.9076G>A	p.G445R	CYP2D6	rs751092905	42126735
777917	91	4046G>A	g.42126746C>T	g.9065G>A	p.R441H	CYP2D6	rs532668079	42126746
777916	91	4045C>T	g.42126747G>A	g.9064C>T	p.R441C	CYP2D6	rs730882251	42126747
777915	91	4043G>A	g.42126749C>T	g.9062G>A	p.R440H	CYP2D6	rs267608319	42126749
777914	91	4040G>A	g.42126752C>T	g.9059G>A	p.G439D	CYP2D6	rs569439709	42126752
777913	91	3915C>T	g.42126877G>A	g.8934C>T	p.P430L	CYP2D6	rs3021084	42126877
3685016	29	c.625G>A	g.38444671G>A	g.15972G>A	p.E209K	RYR1	rs771058055	38444671
3685017	29	c.641C>T	g.38446481C>T	g.17782C>T	p.T214M	RYR1	rs727504129	38446481
3685018	29	c.652G>A	g.38446492G>A	g.17793G>A	p.V218I	RYR1	rs193922759	38446492
3685020	29	c.680A>T	g.38446520A>T	g.17821A>T	p.D227V	RYR1	rs193922760	38446520
777912	91	3896C>T	g.42126896G>A	g.8915C>T	p.Q424X	CYP2D6	rs763964554	42126896
777911	91	3878G>A	g.42126914C>T	g.8897G>A	p.E418K	CYP2D6	rs28371733	42126914
777910	91	3866C>T	g.42126926G>A	g.8885C>T	p.R414C	CYP2D6	rs747089665	42126926
777909	91	3854G>A	g.42126938C>T	g.8873G>A	p.E410K	CYP2D6	rs769157652	42126938
777908	91	3836A>C	g.42126956T>G	g.8855A>C	p.K404Q	CYP2D6	rs1931013246	42126956
2676699	48	3830G>C	g.42126962C>G	g.8849G>C	p.V402L	CYP2D6	rs1602566413	42126962
1103074	79	3810delTC	g.42126982_42126983del	g.8829_8830del	p.L395fs	CYP2D6	rs757396767	42126982
777906	91	3335G>A	g.42127457C>T	g.8354G>A	p.R388H	CYP2D6	rs77312092	42127457
777905	91	3319G>A	g.42127473C>T	g.8338G>A	p.E383K	CYP2D6	rs75386357	42127473
828071	90	663A>G	m.663A>G	\N	\N	MT-RNR1	rs56489998	663
949529	83	50delGAGTCG; 55_56insGAGTCG	g.48037784GAGTCG[2]; g.48037784GAGTCG[4]	g.5218GAGTCG[2]; g.5218GAGTCG[4]	p.del17_18GV; p.V18_V19insGV	NUDT15	rs746071566	48037784
779061	91	7974G>A	g.48045720G>A	g.13154G>A	p.R139H	NUDT15	rs147390019	48045720
779062	91	8025T>A	g.48045771T>A	g.13205T>A	p.L156Q	NUDT15	rs139551410	48045771
3685014	29	c.529C>T	g.38444253C>T	g.15554C>T	p.R177C	RYR1	rs193922757	38444253
3685015	29	c.533A>G; c.533A>C	g.38444257A>G; g.38444257A>C	g.15558A>G; g.15558A>C	p.Y178C; p.Y178S	RYR1	\N	38444257
3685019	29	c.677T>A	g.38446517T>A	g.17818T>A	p.M226K	RYR1	rs112596687	38446517
3685021	29	c.742G>A; c.742G>C	g.38446710G>A; g.38446710G>C	g.18011G>A; g.18011G>C	p.G248R; p.G248R	RYR1	rs1801086	38446710
3685022	29	c.946C>T	g.38448500C>T	g.19801C>T	p.R316C	RYR1	rs752652072	38448500
3685031	29	c.1202G>T; c.1202G>A	g.38451843G>T; g.38451843G>A	g.23144G>T; g.23144G>A	p.R401L; p.R401H	RYR1	rs193922766	38451843
779112	91	c.1209C>G	g.38451850C>G	g.23151C>G	p.I403M	RYR1	rs118192116	38451850
3685033	29	c.1411C>T	g.38452985C>T	g.24286C>T	p.R471C	RYR1	\N	38452985
3685034	29	c.1422G>T	g.38452996G>T	g.24297G>T	p.Q474H	RYR1	rs193922767	38452996
3685035	29	c.1453A>G	g.38455247A>G	g.26548A>G	p.M485V	RYR1	rs147723844	38455247
3685036	29	c.1459C>G	g.38455253C>G	g.26554C>G	p.L487V	RYR1	\N	38455253
3685037	29	c.1460T>C	g.38455254T>C	g.26555T>C	p.L487P	RYR1	\N	38455254
3685038	29	c.1475G>A	g.38455269G>A	g.26570G>A	p.R492H	RYR1	rs901087791	38455269
3685039	29	c.1553T>C	g.38455347T>C	g.26648T>C	p.V518A	RYR1	\N	38455347
3685040	29	c.1565A>C; c.1565A>G	g.38455359A>C; g.38455359A>G	g.26660A>C; g.26660A>G	p.Y522S; p.Y522C	RYR1	rs118192162	38455359
779114	91	c.1589G>A	g.38455463G>A	g.26764G>A	p.R530H	RYR1	rs111888148	38455463
3685042	29	c.1597C>T; c.1597C>A	g.38455471C>T; g.38455471C>A	g.26772C>T; g.26772C>A	p.R533C; p.R533S	RYR1	rs193922768	38455471
779116	91	c.1598G>A	g.38455472G>A	g.26773G>A	p.R533H	RYR1	rs144336148	38455472
3824632	24	c.1615T>C; c.1615T>G	g.38455489T>C; g.38455489T>G	g.26790T>C; g.26790T>G	p.F539L; p.F539V	RYR1	rs193922769	38455489
3685046	29	c.1630G>T	g.38455504G>T	g.26805G>T	p.D544Y	RYR1	\N	38455504
779117	91	c.1654C>T	g.38455528C>T	g.26829C>T	p.R552W	RYR1	rs193922770	38455528
3685048	29	c.1834G>C	g.38457539G>C	g.28840G>C	p.A612P	RYR1	rs118204423	38457539
779118	91	c.1840C>T	g.38457545C>T	g.28846C>T	p.R614C	RYR1	rs118192172	38457545
779119	91	c.1841G>T	g.38457546G>T	g.28847G>T	p.R614L	RYR1	rs193922772	38457546
3685051	29	c.2050G>C	g.38458175G>C	g.29476G>C	p.G684R	RYR1	rs747177274	38458175
3685052	29	c.2122G>A	g.38458247G>A	g.29548G>A	p.D708N	RYR1	rs138874610	38458247
3685053	29	c.2447C>T	g.38460461C>T	g.31762C>T	p.P816L	RYR1	rs376149732	38460461
3685054	29	c.2537C>T	g.38460551C>T	g.31852C>T	p.S846L	RYR1	rs193922775	38460551
3685055	29	c.2654G>A	g.38463499G>A	g.34800G>A	p.R885H	RYR1	rs370634440	38463499
3685056	29	c.2797G>A	g.38464649G>A	g.35950G>A	p.A933T	RYR1	rs148623597	38464649
3685057	29	c.2924G>A	g.38466144G>A	g.37445G>A	p.R975Q	RYR1	rs778241277	38466144
3685059	29	c.3095G>A	g.38466315G>A	g.37616G>A	p.R1032H	RYR1	rs141942845	38466315
3685060	29	c.3127C>T	g.38466347C>T	g.37648C>T	p.R1043C	RYR1	rs111272095	38466347
777651	91	42615T>C	g.94981297T>C	g.48140T>C	p.I359T	CYP2C9	rs56165452	94981297
777935	91	4214G>A	g.42126578C>T	g.9233G>A	p.R497H	CYP2D6	rs1440526469	42126578
1103089	79	4135_4136insTGCCCACTG	g.42126658_42126666dup	g.9146_9154dup	p.468_470dupVPT	CYP2D6	rs765776661	42126658
777921	91	4111C>G	g.42126681G>C	g.9130C>G	p.H463D	CYP2D6	\N	42126681
778215	91	19381G>A	g.99660516C>T	g.24483G>A	p.A337T	CYP3A5	rs28383479	99660516
3685069	29	c.4024A>G	g.38473635A>G	g.44936A>G	p.S1342G	RYR1	rs34694816	38473635
3685070	29	c.4178A>G	g.38475335A>G	g.46636A>G	p.K1393R	RYR1	rs137933390	38475335
3685071	29	c.4400A>G	g.38477816A>G	g.49117A>G	p.K1467R	RYR1	rs145573319	38477816
3685072	29	c.4711A>G	g.38483293A>G	g.54594A>G	p.I1571V	RYR1	rs146429605	38483293
3685073	29	c.4747C>T	g.38483329C>T	g.54630C>T	p.R1583C	RYR1	rs754476250	38483329
3685080	29	c.5183C>T	g.38485838C>T	g.57139C>T	p.S1728F	RYR1	rs193922781	38485838
3685081	29	c.5186T>G	g.38485841T>G	g.57142T>G	p.M1729R	RYR1	rs193922782	38485841
3685082	29	c.5317C>T	g.38485972C>T	g.57273C>T	p.P1773S	RYR1	rs192863857	38485972
3685083	29	c.5341T>C	g.38485996T>C	g.57297T>C	p.C1781R	RYR1	rs372958050	38485996
3685084	29	c.5360C>T	g.38486015C>T	g.57316C>T	p.P1787L	RYR1	rs34934920	38486015
3685085	29	c.5440A>G	g.38486095A>G	g.57396A>G	p.M1814V	RYR1	\N	38486095
3685086	29	c.5441T>A	g.38486096T>A	g.57397T>A	p.M1814K	RYR1	rs193922783	38486096
3685087	29	c.5890C>T	g.38490151C>T	g.61452C>T	p.R1964C	RYR1	rs145801146	38490151
3685088	29	c.6037A>C	g.38490642A>C	g.61943A>C	p.K2013Q	RYR1	\N	38490642
3685089	29	c.6178G>T	g.38492540G>T	g.63841G>T	p.G2060C	RYR1	rs35364374	38492540
3685090	29	c.6302T>A	g.38494379T>A	g.65680T>A	p.M2101K	RYR1	rs746818096	38494379
3685092	29	c.6349G>C	g.38494426G>C	g.65727G>C	p.V2117L	RYR1	rs193922788	38494426
3685093	29	c.6377G>A	g.38494454G>A	g.65755G>A	p.R2126Q	RYR1	\N	38494454
3685094	29	c.6387C>G	g.38494464C>G	g.65765C>G	p.D2129E	RYR1	rs117886618	38494464
3685095	29	c.6388G>A	g.38494465G>A	g.65766G>A	p.G2130R	RYR1	rs193922789	38494465
3685096	29	c.6478G>A	g.38494555G>A	g.65856G>A	p.G2160S	RYR1	rs143398211	38494555
779120	91	c.6487C>T	g.38494564C>T	g.65865C>T	p.R2163C	RYR1	rs118192175	38494564
3685098	29	c.6488G>A; c.6488G>C; c.6488G>T	g.38494565G>A; g.38494565G>C; g.38494565G>T	g.65866G>A; g.65866G>C; g.65866G>T	p.R2163H; p.R2163P; p.R2163L	RYR1	rs118192163	38494565
779122	91	c.6502G>A	g.38494579G>A	g.65880G>A	p.V2168M	RYR1	rs118192176	38494579
3685101	29	c.6548G>A	g.38494625G>A	g.65926G>A	p.G2183E	RYR1	rs959170123	38494625
3685102	29	c.6599C>T	g.38496265C>T	g.67566C>T	p.A2200V	RYR1	rs193922791	38496265
3685103	29	c.6612C>G	g.38496278C>G	g.67579C>G	p.H2204Q	RYR1	rs141646642	38496278
779123	91	c.6617C>G; c.6617C>T	g.38496283C>G; g.38496283C>T	g.67584C>G; g.67584C>T	p.T2206R; p.T2206M	RYR1	rs118192177	38496283
3685105	29	c.6628G>T	g.38496294G>T	g.67595G>T	p.V2210F	RYR1	rs193922792	38496294
3685106	29	c.6635T>A	g.38496301T>A	g.67602T>A	p.V2212D	RYR1	rs193922793	38496301
777260	91	c.520C>T	g.201091993G>A	g.25574C>T	p.R174W	CACNA1S	rs772226819	201091993
777261	91	c.3257G>A	g.201060815C>T	g.56752G>A	p.R1086H	CACNA1S	rs1800559	201060815
777303	91	711+3A->G	g.117534368A>G	g.73585A>G	Intronic	CFTR	rs397508761	117534368
778210	91	3699C>T	g.99676198G>A	g.8801C>T	p.R28C	CYP3A5	rs55817950	99676198
778211	91	6981A>G	g.99672916T>C	g.12083A>G	splicing defect	CYP3A5	rs776746	99672916
778214	91	14685G>A	g.99665212C>T	g.19787G>A	splicing defect	CYP3A5	rs10264272	99665212
948626	83	27126_27127insT	g.99652771dup	g.32228dup	p.T346fs	CYP3A5	rs41303343	99652771
3685008	29	c.488G>T; c.488G>A	g.38444212G>T; g.38444212G>A	g.15513G>T; g.15513G>A	p.R163L; p.R163H	RYR1	rs193922753	38444212
3685058	29	c.2996G>A	g.38466216G>A	g.37517G>A	p.R999H	RYR1	rs180714609	38466216
3824648	24	c.3166G>C; c.3166G>A	g.38466386G>C; g.38466386G>A	g.37687G>C; g.37687G>A	p.D1056H; p.D1056N	RYR1	rs2145447772	38466386
3685063	29	c.3172G>A	g.38466392G>A	g.37693G>A	p.E1058K	RYR1	\N	38466392
3685064	29	c.3224G>A	g.38467655G>A	g.38956G>A	p.R1075Q	RYR1	rs749040743	38467655
3685065	29	c.3418C>T	g.38469002C>T	g.40303C>T	p.R1140C	RYR1	rs193922776	38469002
3685066	29	c.3527C>T	g.38469111C>T	g.40412C>T	p.T1176I	RYR1	rs549201486	38469111
3685067	29	c.3656A>C	g.38469404A>C	g.40705A>C	p.Q1219P	RYR1	\N	38469404
3685068	29	c.3667G>A	g.38469415G>A	g.40716G>A	p.E1223K	RYR1	rs936513262	38469415
3685074	29	c.4763C>T	g.38483345C>T	g.54646C>T	p.P1588L	RYR1	rs151029675	38483345
3685075	29	c.4775C>T	g.38483357C>T	g.54658C>T	p.P1592L	RYR1	rs193922777	38483357
3685076	29	c.5024T>C	g.38485679T>C	g.56980T>C	p.L1675P	RYR1	\N	38485679
3685077	29	c.5033A>G	g.38485688A>G	g.56989A>G	p.N1678S	RYR1	rs781104539	38485688
3685078	29	c.5036G>A	g.38485691G>A	g.56992G>A	p.R1679H	RYR1	rs146504767	38485691
3685079	29	c.5132A>G	g.38485787A>G	g.57088A>G	p.Y1711C	RYR1	rs754785770	38485787
3685091	29	c.6304G>C	g.38494381G>C	g.65682G>C	p.V2102L	RYR1	rs770593660	38494381
2784565	46	18833C>A	g.15878779G>T	g.24296C>A	p.L519M	CYP4F2	rs3093200	15878779
3685107	29	c.6640G>A	g.38496306G>A	g.67607G>A	p.V2214I	RYR1	rs193922795	38496306
778236	91	34T>G	g.15897578A>C	g.5497T>G	p.W12G	CYP4F2	rs3093105	15897578
777268	91	E56K	g.117509035G>A	g.48252G>A	p.E56K	CFTR	rs397508256	117509035
2784562	46	46G>C	g.15897566C>G	g.5509G>C	p.A16P	CYP4F2	rs114099324	15897566
3318560	35	139C>T	g.15897473G>A	g.5602C>T	p.R74C	CYP4F2	rs115517770	15897473
3318561	35	146G>A	g.15897466C>T	g.5609G>A	p.R49Q	CYP4F2	rs201380574	15897466
3318562	35	2052C>A	g.15895560G>T	g.7515C>A	p.P97T	CYP4F2	rs144455532	15895560
3318563	35	2085C>T	g.15895527G>A	g.7548C>T	p.R108W	CYP4F2	rs114396708	15895527
3318564	35	5071G>A	g.15892541C>T	g.10534G>A	p.E129L	CYP4F2	rs145875499	15892541
3318566	35	7941G>T	g.15889671C>A	g.13404G>T	p.A224S	CYP4F2	rs144233412	15889671
3318567	35	11594C>G	g.15886018G>C	g.17057C>G	p.L341V	CYP4F2	rs145174239	15886018
778237	91	17991G>A	g.15879621C>T	g.23454G>A	p.V433M	CYP4F2	rs2108622	15879621
3318569	35	18200G>A	g.15879412C>T	g.23663G>A	p.R444H	CYP4F2	rs138971789	15879412
3685110	29	c.6710G>A	g.38496455G>A	g.67756G>A	p.C2237Y	RYR1	\N	38496455
3685111	29	c.6742C>T	g.38496487C>T	g.67788C>T	p.R2248C	RYR1	rs763352221	38496487
3685112	29	c.6743G>A	g.38496488G>A	g.67789G>A	p.R2248H	RYR1	rs140152019	38496488
3685113	29	c.6757C>T	g.38496502C>T	g.67803C>T	p.H2253Y	RYR1	rs917523269	38496502
3685114	29	c.6838G>A	g.38496901G>A	g.68202G>A	p.V2280I	RYR1	rs193922797	38496901
3685115	29	c.6847A>C	g.38496910A>C	g.68211A>C	p.N2283H	RYR1	rs118192121	38496910
3685116	29	c.6961A>G	g.38499177A>G	g.70478A>G	p.I2321V	RYR1	rs34390345	38499177
779124	91	c.7007G>A	g.38499223G>A	g.70524G>A	p.R2336H	RYR1	rs112563513	38499223
3685118	29	c.7018T>C	g.38499234T>C	g.70535T>C	p.F2340L	RYR1	\N	38499234
3685119	29	c.7025A>G	g.38499241A>G	g.70542A>G	p.N2342S	RYR1	rs147213895	38499241
3685120	29	c.7032G>C	g.38499639G>C	g.70940G>C	p.E2344D	RYR1	rs193922798	38499639
3685121	29	c.7035C>A	g.38499642C>A	g.70943C>A	p.S2345R	RYR1	\N	38499642
3685122	29	c.7036G>A	g.38499643G>A	g.70944G>A	p.V2346M	RYR1	rs193922799	38499643
779125	91	c.7042_7044del	g.38499646_38499648delGAG	g.70947_70949delGAG	p.E2348del	RYR1	rs121918596	38499646
3685124	29	c.7043A>G	g.38499650A>G	g.70951A>G	p.E2348G	RYR1	rs193922801	38499650
779126	91	c.7048G>A	g.38499655G>A	g.70956G>A	p.A2350T	RYR1	rs193922802	38499655
3685126	29	c.7060G>A	g.38499667G>A	g.70968G>A	p.V2354M	RYR1	\N	38499667
779127	91	c.7063C>T	g.38499670C>T	g.70971C>T	p.R2355W	RYR1	rs193922803	38499670
3685128	29	c.7073T>A	g.38499680T>A	g.70981T>A	p.I2358N	RYR1	\N	38499680
3685129	29	c.7076G>A	g.38499683G>A	g.70984G>A	p.R2359Q	RYR1	\N	38499683
3685130	29	c.7075C>T	g.38499682C>T	g.70983C>T	p.R2359W	RYR1	rs769482889	38499682
3685131	29	c.7084G>A	g.38499691G>A	g.70992G>A	p.E2362K	RYR1	rs762401851	38499691
3685132	29	c.7085A>G	g.38499692A>G	g.70993A>G	p.E2362G	RYR1	rs193922804	38499692
3685133	29	c.7089C>G	g.38499696C>G	g.70997C>G	p.C2363W	RYR1	\N	38499696
3685134	29	c.7090T>G	g.38499697T>G	g.70998T>G	p.F2364V	RYR1	rs193922805	38499697
3685135	29	c.7097C>G	g.38499704C>G	g.71005C>G	p.P2366R	RYR1	rs193922806	38499704
3685136	29	c.7099G>A	g.38499706G>A	g.71007G>A	p.A2367T	RYR1	rs146306934	38499706
3685137	29	c.7112A>G	g.38499719A>G	g.71020A>G	p.E2371G	RYR1	\N	38499719
3685138	29	c.7123G>A	g.38499730G>A	g.71031G>A	p.G2375R	RYR1	\N	38499730
779128	91	c.7124G>C	g.38499731G>C	g.71032G>C	p.G2375A	RYR1	rs193922807	38499731
3685140	29	c.7199A>G	g.38499806A>G	g.71107A>G	p.D2400G	RYR1	rs976108591	38499806
3685141	29	c.7210G>A	g.38499817G>A	g.71118G>A	p.E2404K	RYR1	rs111364296	38499817
779129	91	c.7282G>A	g.38499975G>A	g.71276G>A	p.A2428T	RYR1	rs193922809	38499975
3685143	29	c.7291G>A; c.7291G>T	g.38499984G>A; g.38499984G>T	g.71285G>A; g.71285G>T	p.D2431N; p.D2431Y	RYR1	rs193922810	38499984
3685144	29	c.7292A>T	g.38499985A>T	g.71286A>T	p.D2431V	RYR1	\N	38499985
779130	91	c.7300G>A	g.38499993G>A	g.71294G>A	p.G2434R	RYR1	rs121918593	38499993
3685146	29	c.7304G>A; c.7304G>T	g.38499997G>A; g.38499997G>T	g.71298G>A; g.71298G>T	p.R2435H; p.R2435L	RYR1	rs28933396	38499997
3685147	29	c.7307G>A	g.38500000G>A	g.71301G>A	p.C2436Y	RYR1	\N	38500000
3685148	29	c.7310C>T	g.38500003C>T	g.71304C>T	p.A2437V	RYR1	rs193922812	38500003
3685149	29	c.7317G>C	g.38500010G>C	g.71311G>C	p.E2439D	RYR1	rs193922813	38500010
779132	91	c.7354C>T	g.38500636C>T	g.71937C>T	p.R2452W	RYR1	rs118192124	38500636
3685152	29	c.7358T>C	g.38500640T>C	g.71941T>C	p.I2453T	RYR1	rs118192123	38500640
779133	91	c.7360C>T	g.38500642C>T	g.71943C>T	p.R2454C	RYR1	rs193922816	38500642
779134	91	c.7361G>A	g.38500643G>A	g.71944G>A	p.R2454H	RYR1	rs118192122	38500643
779135	91	c.7372C>T	g.38500654C>T	g.71955C>T	p.R2458C	RYR1	rs28933397	38500654
3685156	29	c.7373G>A; c.7373G>T	g.38500655G>A; g.38500655G>T	g.71956G>A; g.71956G>T	p.R2458H; p.R2458L	RYR1	rs121918594	38500655
3685157	29	c.7385C>T	g.38500667C>T	g.71968C>T	p.P2462L	RYR1	rs551223467	38500667
3685162	29	c.7760A>G	g.38502652A>G	g.73953A>G	p.Y2587C	RYR1	rs767553612	38502652
3685163	29	c.7771C>G; c.7771C>T	g.38502663C>G; g.38502663C>T	g.73964C>G; g.73964C>T	p.R2591G; p.R2591W	RYR1	rs193922822	38502663
3685164	29	c.7777C>G	g.38502669C>G	g.73970C>G	p.R2593G	RYR1	\N	38502669
3685165	29	c.7778G>A	g.38502670G>A	g.73971G>A	p.R2593H	RYR1	rs751180702	38502670
3685166	29	c.7787C>T	g.38502679C>T	g.73980C>T	p.T2596I	RYR1	rs193922824	38502679
3685167	29	c.7816T>A	g.38502708T>A	g.74009T>A	p.C2606S	RYR1	rs748575133	38502708
3685168	29	c.7879G>C; c.7879G>A	g.38502923G>C; g.38502923G>A	g.74224G>C; g.74224G>A	p.V2627L; p.V2627M	RYR1	rs914804033	38502923
779264	91	60979T>G	g.21202553T>G	g.76360T>G	p.F400V	SLCO1B1	rs1228465562	21202553
1508723	71	421C>A	g.88131171G>T	g.105152C>A	Q141K	ABCG2	rs2231142	88131171
778247	91	c.85T>C	g.97883329A>G	g.42731T>C	p.C29R	DPYD	rs1801265	97883329
778249	91	c.313G>A	g.97740400C>T	g.185660G>A	p.A105T	DPYD	rs150385342	97740400
778250	91	c.343A>G	g.97721650T>C	g.204410A>G	p.M115V	DPYD	rs141462178	97721650
778251	91	c.451A>G	g.97721542T>C	g.204518A>G	p.N151D	DPYD	rs200562975	97721542
778252	91	c.496A>G	g.97699535T>C	g.226525A>G	p.M166V	DPYD	rs2297595	97699535
778253	91	c.498G>A	g.97699533C>T	g.226527G>A	p.M166I	DPYD	rs139834141	97699533
3685029	29	c.1144C>A	g.38451785C>A	g.23086C>A	p.H382N	RYR1	\N	38451785
3685030	29	c.1201C>T; c.1201C>A; c.1201C>G	g.38451842C>T; g.38451842C>A; g.38451842C>G	g.23143C>T; g.23143C>A; g.23143C>G	p.R401C; p.R401S; p.R401G	RYR1	rs193922764	38451842
779365	91	340G>A	g.18143622C>T	g.16522G>A	p.E114K	TPMT	rs115106679	18143622
778245	91	c.61C>T	g.97883353G>A	g.42707C>T	p.R21X	DPYD	rs72549310	97883353
778246	91	c.62G>A	g.97883352C>T	g.42708G>A	p.R21Q	DPYD	rs80081766	97883352
778254	91	c.525G>A	g.97699506C>T	g.226554G>A	p.S175S	DPYD	rs6670886	97699506
778255	91	c.557A>G	g.97699474T>C	g.226586A>G	p.Y186C	DPYD	rs115232898	97699474
778256	91	c.601A>C	g.97699430T>G	g.226630A>C	p.S201R	DPYD	rs72549308	97699430
778257	91	c.632A>G	g.97699399T>C	g.226661A>G	p.Y211C	DPYD	rs72549307	97699399
778258	91	c.703C>T	g.97691776G>A	g.234284C>T	p.R235W	DPYD	rs1801266	97691776
778259	91	c.775A>G	g.97679170T>C	g.246890A>G	p.K259E	DPYD	rs45589337	97679170
778260	91	c.868A>G	g.97595149T>C	g.330911A>G	p.K290E	DPYD	rs146356975	97595149
778261	91	c.929T>C	g.97595088A>G	g.330972T>C	p.L310S	DPYD	rs150437414	97595088
778262	91	c.934C>T	g.97595083G>A	g.330977C>T	p.L312F	DPYD	rs145112791	97595083
778263	91	c.967G>A	g.97593379C>T	g.332681G>A	p.A323T	DPYD	rs201018345	97593379
778264	91	c.1003G>T	g.97593343C>A	g.332717G>T	p.V335L	DPYD	rs72549306	97593343
778265	91	c.1024G>A	g.97593322C>T	g.332738G>A	p.D342N	DPYD	rs183385770	97593322
778266	91	c.1057C>T	g.97593289G>A	g.332771C>T	p.R353C	DPYD	rs143154602	97593289
778267	91	c.1108A>G	g.97593238T>C	g.332822A>G	p.I370V	DPYD	rs72549305	97593238
778268	91	c.1129-5923C>G	g.97579893G>C	g.346167C>G	splicing defect	DPYD	rs75017182	97579893
778270	91	c.1156G>T	g.97573943C>A	g.352117G>T	p.E386X	DPYD	rs78060119	97573943
778271	91	c.1180C>T	g.97573919G>A	g.352141C>T	p.R394W	DPYD	rs140602333	97573919
778272	91	c.1181G>T	g.97573918C>A	g.352142G>T	p.R394L	DPYD	rs143815742	97573918
778273	91	c.1218G>A	g.97573881C>T	g.352179G>A	p.M406I	DPYD	rs61622928	97573881
778269	91	c.1236G>A	g.97573863C>T	g.352197G>A	\N	DPYD	rs56038477	97573863
778274	91	c.1260T>A	g.97573839A>T	g.352221T>A	p.N420K	DPYD	rs200064537	97573839
778276	91	c.1294G>A	g.97573805C>T	g.352255G>A	p.D432N	DPYD	rs142512579	97573805
778278	91	c.1349C>T	g.97549735G>A	g.376325C>T	p.A450V	DPYD	rs72975710	97549735
778279	91	c.1358C>G	g.97549726G>C	g.376334C>G	p.P453R	DPYD	rs144395748	97549726
778280	91	c.1371C>T	g.97549713G>A	g.376347C>T	p.N457N	DPYD	rs57918000	97549713
778282	91	c.1475C>T	g.97549609G>A	g.376451C>T	p.S492L	DPYD	rs72549304	97549609
778283	91	c.1484A>G	g.97549600T>C	g.376460A>G	p.D495G	DPYD	rs111858276	97549600
778284	91	c.1519G>A	g.97549565C>T	g.376495G>A	p.V507I	DPYD	rs138391898	97549565
778285	91	c.1543G>A	g.97515923C>T	g.410137G>A	p.V515I	DPYD	rs148994843	97515923
778286	91	c.1577C>G	g.97515889G>C	g.410171C>G	p.T526S	DPYD	rs190951787	97515889
778287	91	c.1601G>A	g.97515865C>T	g.410195G>A	p.S534N	DPYD	rs1801158	97515865
778288	91	c.1615G>A	g.97515851C>T	g.410209G>A	p.G539R	DPYD	rs142619737	97515851
778289	91	c.1627A>G	g.97515839T>C	g.410221A>G	p.I543V	DPYD	rs1801159	97515839
778290	91	c.1679T>G	g.97515787A>C	g.410273T>G	p.I560S	DPYD	rs55886062	97515787
778291	91	c.1682G>T	g.97515784C>A	g.410276G>T	p.R561L	DPYD	rs201615754	97515784
778292	91	c.1774C>T	g.97450190G>A	g.475870C>T	p.R592W	DPYD	rs59086055	97450190
778293	91	c.1775G>A	g.97450189C>T	g.475871G>A	p.R592Q	DPYD	rs138616379	97450189
778294	91	c.1777G>A	g.97450187C>T	g.475873G>A	p.G593R	DPYD	rs145773863	97450187
778295	91	c.1796T>C	g.97450168A>G	g.475892T>C	p.M599T	DPYD	rs147601618	97450168
778296	91	c.1896T>C	g.97450068A>G	g.475992T>C	p.F632F	DPYD	rs17376848	97450068
948707	83	c.1898del	g.97450067del	g.475994del	p.P633Qfs	DPYD	rs72549303	97450067
778298	91	c.1905C>G	g.97450059G>C	g.476001C>G	p.N635K	DPYD	rs3918289	97450059
778299	91	c.1905+1G>A	g.97450058C>T	g.476002G>A	splicing defect	DPYD	rs3918290	97450058
778300	91	c.1906A>C	g.97382461T>G	g.543599A>C	p.I636L	DPYD	rs55971861	97382461
778301	91	c.1990G>T	g.97373629C>A	g.552431G>T	p.A664S	DPYD	rs138545885	97373629
778302	91	c.2021G>A	g.97373598C>T	g.552462G>A	p.G674D	DPYD	rs137999090	97373598
778303	91	c.2161G>A	g.97306195C>T	g.619865G>A	p.A721T	DPYD	rs145548112	97306195
778304	91	c.2186C>T	g.97305372G>A	g.620688C>T	p.A729V	DPYD	rs146529561	97305372
778305	91	c.2194G>A	g.97305364C>T	g.620696G>A	p.V732I	DPYD	rs1801160	97305364
778306	91	c.2195T>G	g.97305363A>C	g.620697T>G	p.V732G	DPYD	rs60511679	97305363
778307	91	c.2279C>T	g.97305279G>A	g.620781C>T	p.T760I	DPYD	rs112766203	97305279
778308	91	c.2303C>A	g.97234991G>T	g.691069C>A	p.T768K	DPYD	rs56005131	97234991
778310	91	c.2482G>A	g.97193209C>T	g.732851G>A	p.E828K	DPYD	rs200687447	97193209
778311	91	c.2582A>G	g.97193109T>C	g.732951A>G	p.K861R	DPYD	rs60139309	97193109
778316	91	c.2846A>T	g.97082391T>A	g.843669A>T	p.D949V	DPYD	rs67376798	97082391
3685025	29	c.992_994dup	g.38448680_38448681insGGA	g.19981_19982insGGA	p.E331dup	RYR1	\N	38448680
3685027	29	c.1024G>A	g.38448715G>A	g.20016G>A	p.E342K	RYR1	\N	38448715
3685028	29	c.1100G>A; c.1100G>T	g.38448791G>A; g.38448791G>T	g.20092G>A; g.20092G>T	p.R367Q; p.R367L	RYR1	rs113332073	38448791
778319	91	c.2921A>T	g.97079133T>A	g.846927A>T	p.D974V	DPYD	rs72547602	97079133
778320	91	c.2933A>G	g.97079121T>C	g.846939A>G	p.H978R	DPYD	rs72547601	97079121
778322	91	c.2977C>T	g.97079077G>A	g.846983C>T	p.L993F	DPYD	rs202144771	97079077
778321	91	c.2978T>G	g.97079076A>C	g.846984T>G	p.L993R	DPYD	rs139459586	97079076
3685170	29	c.8026C>T	g.38504319C>T	g.75620C>T	p.R2676W	RYR1	rs193922826	38504319
3685171	29	c.8054C>T	g.38504347C>T	g.75648C>T	p.S2685F	RYR1	rs781126470	38504347
778323	91	c.2983G>T	g.97079071C>A	g.846989G>T	p.V995F	DPYD	rs1801268	97079071
778326	91	c.3067C>A	g.97078987G>T	g.847073C>A	p.P1023T	DPYD	rs114096998	97078987
3685108	29	c.6671G>A	g.38496416G>A	g.67717G>A	p.R2224H	RYR1	rs537994744	38496416
3685109	29	c.6670C>T	g.38496415C>T	g.67716C>T	p.R2224C	RYR1	rs199870223	38496415
3685169	29	c.8005G>A	g.38504298G>A	g.75599G>A	p.E2669K	RYR1	\N	38504298
3685172	29	c.8188G>C	g.38504868G>C	g.76169G>C	p.D2730H	RYR1	rs193922827	38504868
3685173	29	c.8189A>G	g.38504869A>G	g.76170A>G	p.D2730G	RYR1	rs112196644	38504869
3685174	29	c.8198G>A	g.38504878G>A	g.76179G>A	p.G2733D	RYR1	rs193922828	38504878
3685175	29	c.8290G>A	g.38505061G>A	g.76362G>A	p.E2764K	RYR1	rs193922829	38505061
3685176	29	c.8327C>T	g.38505325C>T	g.76626C>T	p.S2776F	RYR1	rs147707463	38505325
3685177	29	c.8360C>G	g.38505358C>G	g.76659C>G	p.T2787S	RYR1	rs35180584	38505358
3685178	29	c.8518C>T	g.38505923C>T	g.77224C>T	p.R2840W	RYR1	rs193922830	38505923
3685179	29	c.8527T>C	g.38505932T>C	g.77233T>C	p.S2843P	RYR1	rs768535909	38505932
3685180	29	c.8600T>A	g.38506361T>A	g.77662T>A	p.L2867Q	RYR1	rs193922831	38506361
3685181	29	c.8638G>A	g.38506492G>A	g.77793G>A	p.E2880K	RYR1	rs112772310	38506492
3685182	29	c.8654C>G	g.38506508C>G	g.77809C>G	p.T2885R	RYR1	\N	38506508
3685183	29	c.8729C>T	g.38506865C>T	g.78166C>T	p.T2910M	RYR1	\N	38506865
3685184	29	c.8926C>T	g.38507821C>T	g.79122C>T	p.H2976Y	RYR1	\N	38507821
3685186	29	c.9268G>A	g.38512279G>A	g.83580G>A	p.A3090T	RYR1	\N	38512279
779139	91	c.9310G>A	g.38512321G>A	g.83622G>A	p.E3104K	RYR1	rs193922832	38512321
3685188	29	c.9356G>A	g.38512367G>A	g.83668G>A	p.R3119H	RYR1	rs193922833	38512367
3685189	29	c.9499C>T	g.38515052C>T	g.86353C>T	p.R3167Term	RYR1	\N	38515052
3685190	29	c.9635A>G	g.38516167A>G	g.87468A>G	p.E3212G	RYR1	rs199738299	38516167
3685191	29	c.9649T>C	g.38516181T>C	g.87482T>C	p.S3217P	RYR1	\N	38516181
3685192	29	c.9652G>A	g.38516184G>A	g.87485G>A	p.V3218M	RYR1	rs553055844	38516184
3685193	29	c.9676G>C	g.38516208G>C	g.87509G>C	p.E3226Q	RYR1	\N	38516208
3685194	29	c.9758T>C	g.38517431T>C	g.88732T>C	p.I3253T	RYR1	rs375626634	38517431
3685195	29	c.9797T>C	g.38517470T>C	g.88771T>C	p.M3266T	RYR1	\N	38517470
3685197	29	c.9850T>A	g.38517523T>A	g.88824T>A	p.W3284R	RYR1	\N	38517523
3685198	29	c.9868G>A	g.38517541G>A	g.88842G>A	p.E3290K	RYR1	rs112151058	38517541
3685199	29	c.10042C>T	g.38519237C>T	g.90538C>T	p.R3348C	RYR1	rs118204421	38519237
3685200	29	c.10043G>A	g.38519238G>A	g.90539G>A	p.R3348H	RYR1	rs193922834	38519238
3685201	29	c.10097G>A	g.38519292G>A	g.90593G>A	p.R3366H	RYR1	rs137932199	38519292
3685202	29	c.10100A>G	g.38519295A>G	g.90596A>G	p.K3367R	RYR1	rs118192126	38519295
3685203	29	c.10229C>A	g.38519424C>A	g.90725C>A	p.P3410Q	RYR1	\N	38519424
3685204	29	c.10237A>T	g.38519432A>T	g.90733A>T	p.I3413F	RYR1	\N	38519432
3685205	29	c.10252A>G	g.38519447A>G	g.90748A>G	p.N3418D	RYR1	\N	38519447
3685206	29	c.10556C>T	g.38525432C>T	g.96733C>T	p.P3519L	RYR1	\N	38525432
3685207	29	c.10616G>A	g.38525492G>A	g.96793G>A	p.R3539H	RYR1	rs143987857	38525492
3685208	29	c.10747G>C	g.38527707G>C	g.99008G>C	p.E3583Q	RYR1	rs55876273	38527707
3685209	29	c.10750G>C	g.38527710G>C	g.99011G>C	p.E3584Q	RYR1	\N	38527710
3685210	29	c.10891G>T	g.38528372G>T	g.99673G>T	p.A3631S	RYR1	\N	38528372
3685211	29	c.11086G>C	g.38529002G>C	g.100303G>C	p.D3696H	RYR1	\N	38529002
3685212	29	c.11120G>T	g.38529036G>T	g.100337G>T	p.R3707L	RYR1	rs193922838	38529036
3685213	29	c.11126C>T	g.38529042C>T	g.100343C>T	p.A3709V	RYR1	\N	38529042
3685214	29	c.11132C>T	g.38529048C>T	g.100349C>T	p.T3711M	RYR1	rs375915752	38529048
3685215	29	c.11266C>G	g.38534726C>G	g.106027C>G	p.Q3756E	RYR1	rs4802584	38534726
3685216	29	c.11315G>A	g.38534775G>A	g.106076G>A	p.R3772Q	RYR1	rs193922839	38534775
3685217	29	c.11314C>T	g.38534774C>T	g.106075C>T	p.R3772W	RYR1	rs763112609	38534774
3685218	29	c.11416G>A	g.38535197G>A	g.106498G>A	p.G3806R	RYR1	rs111565359	38535197
3685219	29	c.11518G>A	g.38535998G>A	g.107299G>A	p.V3840I	RYR1	rs140616359	38535998
3685220	29	c.11708G>A	g.38543365G>A	g.114666G>A	p.R3903Q	RYR1	rs148399313	38543365
3685221	29	c.11723A>T	g.38543380A>T	g.114681A>T	p.N3908I	RYR1	\N	38543380
3685222	29	c.11748T>G	g.38543405T>G	g.114706T>G	p.I3916M	RYR1	rs193922840	38543405
3685223	29	c.11798A>G	g.38543551A>G	g.114852A>G	p.Y3933C	RYR1	rs147136339	38543551
3685224	29	c.11813G>A	g.38543566G>A	g.114867G>A	p.G3938D	RYR1	\N	38543566
3685225	29	c.11947C>T	g.38543810C>T	g.115111C>T	p.R3983C	RYR1	\N	38543810
3685226	29	c.11953T>C	g.38543816T>C	g.115117T>C	p.W3985R	RYR1	rs118204422	38543816
3685227	29	c.11958C>G	g.38543821C>G	g.115122C>G	p.D3986E	RYR1	rs193922842	38543821
779140	91	c.11969G>T	g.38543832G>T	g.115133G>T	p.G3990V	RYR1	rs193922843	38543832
3685229	29	c.12028G>A	g.38546460G>A	g.117761G>A	p.E4010K	RYR1	rs755088027	38546460
3685230	29	c.12064A>G	g.38546496A>G	g.117797A>G	p.M4022V	RYR1	rs773040531	38546496
3685231	29	c.12115A>T	g.38548253A>T	g.119554A>T	p.I4039F	RYR1	\N	38548253
3685232	29	c.12121C>T	g.38548259C>T	g.119560C>T	p.R4041W	RYR1	rs144685735	38548259
3685233	29	c.12149C>A	g.38548287C>A	g.119588C>A	p.S4050Y	RYR1	rs193922844	38548287
778317	91	c.2872A>G	g.97082365T>C	g.843695A>G	p.K958E	DPYD	rs141044036	97082365
778318	91	c.2915A>G	g.97079139T>C	g.846921A>G	p.Q972R	DPYD	rs145529148	97079139
778495	91	c.40G>A	g.154546116C>T	g.6457G>A	p.G14R	G6PD	\N	154546116
778494	91	c.34G>T	g.154546122C>A	g.6451G>T	p.V12L	G6PD	\N	154546122
778496	91	c.95A>G	g.154546061T>C	g.6512A>G	p.H32R	G6PD	rs137852340	154546061
778497	91	c.99A>G	g.154546057T>C	g.6516A>G	p.I33M	G6PD	\N	154546057
778498	91	c.103_105delATC	g.154546051_154546053delGAT	g.6520_6522delATC	p.I35del	G6PD	rs137852338	154546051
778499	91	c.110T>C	g.154546046A>G	g.6527T>C	p.M37T	G6PD	\N	154546046
778500	91	c.130G>A	g.154536169C>T	g.16404G>A	p.A44T	G6PD	\N	154536169
778501	91	c.131C>G	g.154536168G>C	g.16405C>G	p.A44G	G6PD	rs78478128	154536168
778502	91	c.143T>C	g.154536156A>G	g.16417T>C	p.I48T	G6PD	rs76645461	154536156
778503	91	c.148C>T	g.154536151G>A	g.16422C>T	p.P50S	G6PD	\N	154536151
778504	91	c.159G>C	g.154536045C>G	g.16528G>C	p.W53C	G6PD	\N	154536045
778505	91	c.169C>T	g.154536035G>A	g.16538C>T	p.R57W	G6PD	\N	154536035
778506	91	c.170G>A	g.154536034C>T	g.16539G>A	p.R57E	G6PD	\N	154536034
778507	91	c.172G>A	g.154536032C>T	g.16541G>A	p.D58N	G6PD	rs137852315	154536032
778509	91	c.180_182delTCT	g.154536022_154536024delAGA	g.16549_16551delTCT	p.L61del	G6PD	\N	154536022
778511	91	c.196T>A	g.154536008A>T	g.16565T>A	p.P66I	G6PD	\N	154536008
778513	91	c.208T>C	g.154535996A>G	g.16577T>C	p.Y70H	G6PD	rs137852349	154535996
778514	91	c.209A>G	g.154535995T>C	g.16578A>G	p.Y70C	G6PD	rs782090947	154535995
778515	91	c.224T>C	g.154535980A>G	g.16593T>C	p.L75P	G6PD	\N	154535980
778516	91	c.241C>T	g.154535963G>A	g.16610C>T	p.R81C	G6PD	rs138687036	154535963
778517	91	c.242G>A	g.154535962C>T	g.16611G>A	p.R81H	G6PD	rs782308266	154535962
778518	91	c.274C>T	g.154535379G>A	g.17194C>T	p.P92S	G6PD	\N	154535379
778519	91	c.281_283delAGA	g.154535370_154535372delTCT	g.17201_17203delAGA	p.K95del	G6PD	\N	154535370
778520	91	c.311G>A	g.154535342C>T	g.17231G>A	p.R104H	G6PD	rs181277621	154535342
778521	91	c.317C>G	g.154535336G>C	g.17237C>G	p.S106C	G6PD	rs267606835	154535336
778522	91	c.323T>A	g.154535330A>T	g.17243T>A	p.V108E	G6PD	\N	154535330
778523	91	c.337G>A	g.154535316C>T	g.17257G>A	p.D113N	G6PD	rs5030870	154535316
778524	91	c.352T>C	g.154535301A>G	g.17272T>C	p.Y118H	G6PD	\N	154535301
778525	91	c.375G>T	g.154535278C>A	g.17295G>T	p.M125I	G6PD	\N	154535278
778526	91	c.376A>G	g.154535277T>C	g.17296A>G	p.N126D	G6PD	rs1050829	154535277
778527	91	c.379G>T	g.154535274C>A	g.17299G>T	p.A127S	G6PD	\N	154535274
778529	91	c.384C>T	g.154535269G>A	g.17304C>T	p.L128L	G6PD	\N	154535269
778530	91	c.392G>T	g.154535261C>A	g.17312G>T	p.G131V	G6PD	\N	154535261
778531	91	c.404A>C	g.154535249T>G	g.17324A>C	p.N135T	G6PD	rs782322505	154535249
778532	91	c.406C>T	g.154535247G>A	g.17326C>T	p.R136C	G6PD	\N	154535247
778533	91	c.409C>T	g.154535244G>A	g.17329C>T	p.L137F	G6PD	\N	154535244
778534	91	c.442G>A	g.154535211C>T	g.17362G>A	p.E148K	G6PD	\N	154535211
778535	91	c.463C>G	g.154535190G>C	g.17383C>G	p.H155D	G6PD	\N	154535190
778536	91	c.466G>A	g.154535187C>T	g.17386G>A	p.E156K	G6PD	rs137852313	154535187
778537	91	c.473G>A	g.154535180C>T	g.17393G>A	p.C158Y	G6PD	rs782487723	154535180
778538	91	c.477G>C	g.154535176C>G	g.17397G>C	p.M159I	G6PD	rs370918918	154535176
778548	91	c.535A>T	g.154534447T>A	g.18126A>T	p.S179C	G6PD	\N	154534447
778549	91	c.542A>T	g.154534440T>A	g.18133A>T	p.D181V	G6PD	rs5030872	154534440
778550	91	c.544C>T	g.154534438G>A	g.18135C>T	p.R182W	G6PD	rs267606836	154534438
778552	91	c.563C>T	g.154534419G>A	g.18154C>T	p.S188F	G6PD	rs5030868	154534419
778553	91	c.573C>G	g.154534409G>C	g.18164C>G	p.F191L	G6PD	\N	154534409
778554	91	c.592C>T	g.154534390G>A	g.18183C>T	p.R198C	G6PD	rs137852330	154534390
2406824	53	c.593G>A;c.593G>C	g.154534389C>T;g.154534389C>G	g.18184G>A;g.18184G>C	p.R198H;p.R198P	G6PD	rs137852332	154534389
778556	91	c.595A>G	g.154534387T>C	g.18186A>G	p.I199V	G6PD	rs781865768	154534387
778557	91	c.634A>G	g.154534348T>C	g.18225A>G	p.M212V	G6PD	rs782754619	154534348
778558	91	c.637G>T	g.154534345C>A	g.18228G>T	p.V213L	G6PD	rs137852326	154534345
778559	91	c.648T>G	g.154534157A>C	g.18416T>G	p.F216L	G6PD	rs137852319	154534157
778560	91	c.679C>T	g.154534126G>A	g.18447C>T	p.R227W	G6PD	\N	154534126
2406830	53	c.680G>A;c.680G>T	g.154534125C>T;g.154534125C>A	g.18448G>A;g.18448G>T	p.R227Q;p.R227L	G6PD	rs137852328	154534125
778562	91	c.683_685delACA	g.154534120_154534122delTGT	g.18451_18453delACA	p.N229del	G6PD	\N	154534120
778563	91	c.695G>A	g.154534110C>T	g.18463G>A	p.C232Y	G6PD	\N	154534110
778564	91	c.703C>T	g.154534102G>A	g.18471C>T	p.L235F	G6PD	rs782757170	154534102
778565	91	c.713A>G	g.154534092T>C	g.18481A>G	p.K238R	G6PD	\N	154534092
778566	91	c.724_729delGGCACT	g.154534076_154534081delAGTGCC	g.18492_18497delGGCACT	p.G242_T243del	G6PD	\N	154534076
778567	91	c.769C>G	g.154534036G>C	g.18537C>G	p.R257G	G6PD	\N	154534036
778568	91	c.806G>A	g.154533634C>T	g.18939G>A	p.C269Y	G6PD	rs137852346	154533634
778569	91	c.811G>C	g.154533629C>G	g.18944G>C	p.V271L	G6PD	\N	154533629
778570	91	c.820G>A	g.154533620C>T	g.18953G>A	p.E274K	G6PD	\N	154533620
778571	91	c.821A>T	g.154533619T>A	g.18954A>T	p.E274V	G6PD	\N	154533619
778572	91	c.825G>C	g.154533615C>G	g.18958G>C	p.K275N	G6PD	\N	154533615
778573	91	c.826C>T	g.154533614G>A	g.18959C>T	p.P276S	G6PD	\N	154533614
778574	91	c.832T>C	g.154533608A>G	g.18965T>C	p.S278P	G6PD	\N	154533608
778575	91	c.833C>T	g.154533607G>A	g.18966C>T	p.S278F	G6PD	\N	154533607
2406846	53	c.844G>T;c.844G>C	g.154533596C>A;g.154533596C>G	g.18977G>T;g.18977G>C	p.D282H;p.D282Y	G6PD	rs137852318	154533596
778578	91	c.848A>G	g.154533592T>C	g.18981A>G	p.D283G	G6PD	\N	154533592
778579	91	c.849C>A	g.154533591G>T	g.18982C>A	p.D283E	G6PD	\N	154533591
3685196	29	c.9848G>A	g.38517521G>A	g.88822G>A	p.R3283Q	RYR1	rs757753317	38517521
778493	91	c.25C>T	g.154546131G>A	g.6442C>T	p.R9W	G6PD	\N	154546131
778590	91	c.962G>A	g.154533031C>T	g.19542G>A	p.G321E	G6PD	\N	154533031
777269	91	P67L	g.117509069C>T	g.48286C>T	p.P67L	CFTR	rs368505753	117509069
777273	91	R117C	g.117530974C>T	g.70191C>T	p.R117C	CFTR	rs77834169	117530974
777274	91	R117H/ Class: IV	g.117530975G>A	g.70192G>A	p.R117H	CFTR	rs78655421	117530975
777275	91	G178R	g.117534318G>A	g.73535G>A	p.G178R	CFTR	rs80282562	117534318
777276	91	E193K	g.117534363G>A	g.73580G>A	p.E193K	CFTR	rs397508759	117534363
777277	91	L206W	g.117535285T>G	g.74502T>G	p.L206W	CFTR	rs121908752	117535285
777278	91	R347H/ Class: IV	g.117540270G>A	g.79487G>A	p.R347H	CFTR	rs77932196	117540270
777279	91	R352Q	g.117540285G>A	g.79502G>A	p.R352Q	CFTR	rs121908753	117540285
777280	91	A455E/ Class: V	g.117548795C>A	g.88012C>A	p.A455E	CFTR	rs74551128	117548795
777496	91	-806C>T	g.94761900C>T	g.4220C>T	p.expression	CYP2C19	rs12248560	94761900
3819813	25	4173C>T	g.42126619G>A	g.9192C>T	\N	CYP2D6	rs28371736	42126619
3819812	25	4170T>C	g.42126622A>G	g.9189T>C	\N	CYP2D6	rs747998333	42126622
3819809	25	4167T>C	g.42126625A>G	g.9186T>C	\N	CYP2D6	\N	42126625
3819802	25	4134T>C	g.42126658A>G	g.9153T>C	\N	CYP2D6	rs1135836	42126658
3819798	25	4125G>C	g.42126667C>G	g.9144G>C	\N	CYP2D6	rs1135832	42126667
778580	91	c.851T>C	g.154533589A>G	g.18984T>C	p.V284A	G6PD	\N	154533589
778581	91	c.853C>T	g.154533587G>A	g.18986C>T	p.R285C	G6PD	\N	154533587
778582	91	c.854G>A	g.154533586C>T	g.18987G>A	p.R285H	G6PD	rs74575103	154533586
778583	91	c.871G>A	g.154533122C>T	g.19451G>A	p.V291M	G6PD	rs137852327	154533122
778584	91	c.910G>T	g.154533083C>A	g.19490G>T	p.V303F	G6PD	\N	154533083
778585	91	c.916G>A	g.154533077C>T	g.19496G>A	p.G306S	G6PD	\N	154533077
778586	91	c.921G>C	g.154533072C>G	g.19501G>C	p.Q307H	G6PD	\N	154533072
778587	91	c.929G>A	g.154533064C>T	g.19509G>A	p.G310E	G6PD	\N	154533064
778588	91	c.949G>A	g.154533044C>T	g.19529G>A	p.E317K	G6PD	rs137852339	154533044
778591	91	c.964T>C	g.154533029A>G	g.19544T>C	p.Y322H	G6PD	rs137852347	154533029
778592	91	c.968T>C	g.154533025A>G	g.19548T>C	p.L323P	G6PD	rs76723693	154533025
778593	91	c.977C>A	g.154533016G>T	g.19557C>A	p.P326H	G6PD	\N	154533016
778594	91	c.989G>A	g.154533004C>T	g.19569G>A	p.R330H	G6PD	\N	154533004
778598	91	c.1006A>G	g.154532987T>C	g.19586A>G	p.T336A	G6PD	\N	154532987
778599	91	c.1024C>T	g.154532969G>A	g.19604C>T	p.L342F	G6PD	rs137852342	154532969
778600	91	c.1037A>T	g.154532956T>A	g.19617A>T	p.N346I	G6PD	rs398123544	154532956
778601	91	c.1048G>C	g.154532945C>G	g.19628G>C	p.D350H	G6PD	rs34193178	154532945
778602	91	c.1052G>T	g.154532802C>A	g.19771G>T	p.G351V	G6PD	\N	154532802
778603	91	c.1057C>T	g.154532797G>A	g.19776C>T	p.P353S	G6PD	rs137852333	154532797
778604	91	c.1081G>A	g.154532773C>T	g.19800G>A	p.A361T	G6PD	\N	154532773
778605	91	c.1082C>T	g.154532772G>A	g.19801C>T	p.A361V	G6PD	rs137852345	154532772
778608	91	c.1096A>G	g.154532758T>C	g.19815A>G	p.K366E	G6PD	\N	154532758
778609	91	c.1132G>A	g.154532722C>T	g.19851G>A	p.G378S	G6PD	rs371489738	154532722
778610	91	c.1138A>G	g.154532716T>C	g.19857A>G	p.I380V	G6PD	\N	154532716
778611	91	c.1139T>C	g.154532715A>G	g.19858T>C	p.I380T	G6PD	\N	154532715
778612	91	c.1141T>C	g.154532713A>G	g.19860T>C	p.F381L	G6PD	\N	154532713
778613	91	c.1153T>C	g.154532701A>G	g.19872T>C	p.C385R	G6PD	rs137852322	154532701
778617	91	c.1159C>T	g.154532695G>A	g.19878C>T	p.R387C	G6PD	rs137852334	154532695
778618	91	c.1160G>A	g.154532694C>T	g.19879G>A	p.R387H	G6PD	rs137852321	154532694
778619	91	c.1162A>G	g.154532692T>C	g.19881A>G	p.N388D	G6PD	\N	154532692
3685023	29	c.947G>T	g.38448501G>T	g.19802G>T	p.R316L	RYR1	rs193922761	38448501
777284	91	G551S	g.117587805G>A	g.127022G>A	p.G551S	CFTR	rs121909013	117587805
777285	91	G551D/Class: III	g.117587806G>A	g.127023G>A	p.G551D	CFTR	rs75527207	117587806
777286	91	D579G	g.117590409A>G	g.129626A>G	p.D579G	CFTR	rs397508288	117590409
777287	91	E831X	g.117594930G>T	g.134147G>T	p.E831X	CFTR	rs397508387	117594930
777304	91	2789+5G->A/ Class: V	g.117602868G>A	g.142085G>A	Intronic	CFTR	rs80224560	117602868
777288	91	S945L	g.117603708C>T	g.142925C>T	p.S945L	CFTR	rs397508442	117603708
777289	91	S977F	g.117606695C>T	g.145912C>T	p.S977F	CFTR	rs141033578	117606695
777510	91	12718A>C	g.94775423A>C	g.17743A>C	p.E122A	CYP2C19	rs17885179	94775423
777511	91	12748G>A	g.94775453G>A	g.17773G>A	p.R132Q	CYP2C19	rs72552267	94775453
777512	91	12784G>A	g.94775489G>A	g.17809G>A	p.R144H	CYP2C19	rs17884712	94775489
777648	91	42568C>A	g.94981250C>A	g.48093C>A	p.S343R	CYP2C9	rs750820937	94981250
1932813	62	42576C>T	g.94981258C>T	g.48101C>T	p.P346L	CYP2C9	rs1297714792	94981258
777649	91	42599G>A	g.94981281G>A	g.48124G>A	p.E354K	CYP2C9	rs749060448	94981281
777650	91	42614A>C	g.94981296A>C	g.48139A>C	p.I359L	CYP2C9	rs1057910	94981296
777652	91	42619C>G	g.94981301C>G	g.48144C>G	p.D360E	CYP2C9	rs28371686	94981301
777653	91	42620C>A	g.94981302C>A	g.48145C>A	p.L361I	CYP2C9	rs1250577724	94981302
777654	91	42623C>G	g.94981305C>G	g.48148C>G	p.L362V	CYP2C9	rs578144976	94981305
777858	91	1914G>T	g.42128878C>A	g.6933G>T	p.C191F	CYP2D6	rs747884067	42128878
777857	91	1913T>C	g.42128879A>G	g.6932T>C	p.C191R	CYP2D6	rs2146937045	42128879
777933	91	4181G>C	g.42126611C>G	g.9200G>C	p.S486T	CYP2D6	rs1135840	42126611
777932	91	4169C>G	g.42126623G>C	g.9188C>G	p.A482G	CYP2D6	rs75467367	42126623
777931	91	4168G>A	g.42126624C>T	g.9187G>A	p.A482T	CYP2D6	rs74478221	42126624
777930	91	4165T>G	g.42126627A>C	g.9184T>G	p.F481V	CYP2D6	\N	42126627
777929	91	4159G>C	g.42126633C>G	g.9178G>C	p.G479R	CYP2D6	rs1135837	42126633
777928	91	4158T>G	g.42126634A>C	g.9177T>G	p.H478Q	CYP2D6	\N	42126634
777927	91	4157A>C	g.42126635T>G	g.9176A>C	p.H478P	CYP2D6	rs766507177	42126635
777926	91	4156C>T	g.42126636G>A	g.9175C>T	p.H478Y	CYP2D6	rs28371735	42126636
778244	91	c.46C>G	g.97883368G>C	g.42692C>G	p.L16V	DPYD	rs150036960	97883368
778540	91	c.488G>A	g.154534494C>T	g.18079G>A	p.G163D	G6PD	\N	154534494
778541	91	c.493A>G	g.154534489T>C	g.18084A>G	p.N165D	G6PD	rs137852331	154534489
778542	91	c.496C>T	g.154534486G>A	g.18087C>T	p.R166C	G6PD	\N	154534486
778543	91	c.497G>A	g.154534485C>T	g.18088G>A	p.R166H	G6PD	\N	154534485
778544	91	c.514C>T	g.154534468G>A	g.18105C>T	p.P172S	G6PD	\N	154534468
778545	91	c.517T>C	g.154534465A>G	g.18108T>C	p.F173L	G6PD	rs137852343	154534465
778546	91	c.519C>G	g.154534463G>C	g.18110C>G	p.F173L	G6PD	\N	154534463
778547	91	c.527A>G	g.154534455T>C	g.18118A>G	p.D176G	G6PD	\N	154534455
778615	91	c.1155C>G	g.154532699G>C	g.19874C>G	p.C385W	G6PD	\N	154532699
778616	91	c.1156A>G	g.154532698T>C	g.19875A>G	p.K386E	G6PD	rs137852320	154532698
828072	90	669T>C	m.669T>C	\N	\N	MT-RNR1	\N	669
778620	91	c.1166A>G	g.154532688T>C	g.19885A>G	p.E389G	G6PD	\N	154532688
778621	91	c.1175T>C	g.154532679A>G	g.19894T>C	p.I392T	G6PD	\N	154532679
778622	91	c.1177C>G	g.154532677G>C	g.19896C>G	p.R393G	G6PD	\N	154532677
778623	91	c.1178G>A	g.154532676C>T	g.19897G>A	p.R393H	G6PD	rs137852316	154532676
778632	91	c.1226C>G	g.154532628G>C	g.19945C>G	p.P409R	G6PD	\N	154532628
2406903	53	c.1229G>A;c.1229G>C	g.154532625C>T;g.154532625C>G	g.19948G>A;g.19948G>C	p.G410D;p.G410A	G6PD	rs137852336	154532625
778635	91	c.1231A>G	g.154532623T>C	g.19950A>G	p.M411V	G6PD	\N	154532623
778636	91	c.1246G>A	g.154532608C>T	g.19965G>A	p.E416K	G6PD	\N	154532608
778637	91	c.1264C>G	g.154532590G>C	g.19983C>G	p.L422V	G6PD	\N	154532590
778638	91	c.1284C>A	g.154532570G>T	g.20003C>A	p.Y428X	G6PD	\N	154532570
778639	91	c.1291G>A	g.154532459C>T	g.20114G>A	p.V431M	G6PD	rs782098548	154532459
778640	91	c.1292T>G	g.154532458A>C	g.20115T>G	p.V431G	G6PD	\N	154532458
778641	91	c.1311C>T	g.154532439G>A	g.20134C>T	p.Y437Y	G6PD	rs2230037	154532439
778642	91	c.1316G>C	g.154532434C>G	g.20139G>C	p.Arg439Pro	G6PD	rs137852337	154532434
778643	91	c.1318C>T	g.154532432G>A	g.20141C>T	p.L440F	G6PD	\N	154532432
778644	91	c.1339G>A	g.154532411C>T	g.20162G>A	p.G447R	G6PD	rs137852317	154532411
778645	91	c.1342A>G	g.154532408T>C	g.20165A>G	p.S448G	G6PD	\N	154532408
778646	91	c.1347G>C	g.154532403C>G	g.20170G>C	p.Q449H	G6PD	\N	154532403
778647	91	c.1358T>A	g.154532392A>T	g.20181T>A	p.V453E	G6PD	\N	154532392
778648	91	c.1360C>T	g.154532390G>A	g.20183C>T	p.R454C	G6PD	rs398123546	154532390
778649	91	c.1361G>A	g.154532389C>T	g.20184G>A	p.R454H	G6PD	rs137852324	154532389
778650	91	c.1366G>C	g.154532279C>G	g.20294G>C	p.D456H	G6PD	\N	154532279
778651	91	c.1367A>T	g.154532278T>A	g.20295A>T	p.D456V	G6PD	\N	154532278
778655	91	c.1381G>A	g.154532264C>T	g.20309G>A	p.A461T	G6PD	rs782608284	154532264
778656	91	c.1388G>A	g.154532257C>T	g.20316G>A	p.R463H	G6PD	rs72554664	154532257
778657	91	c.1400C>G	g.154532245G>C	g.20328C>G	p.P467R	G6PD	rs137852344	154532245
778658	91	c.1414A>C	g.154532231T>G	g.20342A>C	p.I472L	G6PD	\N	154532231
778659	91	c.1442C>G	g.154532203G>C	g.20370C>G	p.P481R	G6PD	rs137852348	154532203
778660	91	c.1462G>A	g.154532086C>T	g.20487G>A	p.G488S	G6PD	\N	154532086
778661	91	c.1463G>T	g.154532085C>A	g.20488G>T	p.G488V	G6PD	\N	154532085
778662	91	c.1465C>T	g.154532083G>A	g.20490C>T	p.P489S	G6PD	\N	154532083
778663	91	c.1466C>T	g.154532082G>A	g.20491C>T	p.P489L	G6PD	\N	154532082
3685304	29	c.15060G>C	g.38587363G>C	g.158664G>C	p.W5020C	RYR1	\N	38587363
3685305	29	c.14364+1G>T	g.38578205G>T	g.149506G>T	\N	RYR1	\N	38578205
779247	91	31160C>T	g.21172734C>T	g.46541C>T	p.R57W	SLCO1B1	rs139257324	21172734
779248	91	31202G>A	g.21172776G>A	g.46583G>A	p.G71R	SLCO1B1	rs373327528	21172776
779249	91	31208T>C	g.21172782T>C	g.46589T>C	p.F73L	SLCO1B1	rs56101265	21172782
779250	91	33021T>C	g.21174595T>C	g.48402T>C	p.V82A	SLCO1B1	rs56061388	21174595
778653	91	c.1380G>C	g.154532265C>G	g.20308G>C	p.E460D	G6PD	\N	154532265
2406923	53	c.1387C>A;c.1387C>T	g.154532258G>T;g.154532258G>A	g.20315C>A;g.20315C>T	p.R463S;p.R463C	G6PD	\N	154532258
778664	91	c.1488_1490delGAA	g.154532058_154532060delTTC	g.20513_20515delGAA	p.K497del	G6PD	\N	154532058
778665	91	c.1502T>G	g.154532046A>C	g.20527T>G	p.F501C	G6PD	\N	154532046
3685234	29	c.12242C>T	g.38548380C>T	g.119681C>T	p.T4081M	RYR1	rs373406011	38548380
3685235	29	c.12310G>C	g.38561140G>C	g.132441G>C	p.G4104R	RYR1	\N	38561140
3685236	29	c.12355A>T	g.38561185A>T	g.132486A>T	p.N4119Y	RYR1	rs193922848	38561185
3685237	29	c.12383C>T	g.38561213C>T	g.132514C>T	p.A4128V	RYR1	\N	38561213
3685238	29	c.12398A>G	g.38561228A>G	g.132529A>G	p.E4133G	RYR1	rs201321695	38561228
3685239	29	c.12406C>A	g.38561236C>A	g.132537C>A	p.R4136S	RYR1	rs193922849	38561236
3685240	29	c.12413T>C	g.38561243T>C	g.132544T>C	p.I4138T	RYR1	rs193922850	38561243
3685241	29	c.12532G>A	g.38561362G>A	g.132663G>A	p.G4178S	RYR1	\N	38561362
3685242	29	c.12533G>T	g.38561363G>T	g.132664G>T	p.G4178V	RYR1	\N	38561363
3685243	29	c.12553G>A	g.38561383G>A	g.132684G>A	p.A4185T	RYR1	rs151119428	38561383
3685244	29	c.12689T>G	g.38565023T>G	g.136324T>G	p.M4230R	RYR1	\N	38565023
3685245	29	c.12700G>C; c.12700G>T	g.38565034G>C; g.38565034G>T	g.136335G>C; g.136335G>T	p.V4234L; p.V4234L	RYR1	rs193922852	38565034
3685246	29	c.12848A>T	g.38565182A>T	g.136483A>T	p.E4283V	RYR1	rs193922853	38565182
3685247	29	c.12881C>T	g.38565215C>T	g.136516C>T	p.T4294M	RYR1	rs587784372	38565215
3685248	29	c.12884C>T	g.38565218C>T	g.136519C>T	p.A4295V	RYR1	rs193922855	38565218
3685249	29	c.13505A>G	g.38566978A>G	g.138279A>G	p.E4502G	RYR1	rs139647387	38566978
3685250	29	c.13513G>C	g.38566986G>C	g.138287G>C	p.D4505H	RYR1	rs150396398	38566986
3685251	29	c.13673G>A	g.38570620G>A	g.141921G>A	p.R4558Q	RYR1	rs118192130	38570620
3685252	29	c.13672C>T	g.38570619C>T	g.141920C>T	p.R4558W	RYR1	rs771741606	38570619
3685253	29	c.13702C>G	g.38570649C>G	g.141950C>G	p.L4568V	RYR1	\N	38570649
3685254	29	c.13760C>T	g.38572032C>T	g.143333C>T	p.P4587L	RYR1	rs143520367	38572032
3685255	29	c.13913G>A	g.38572185G>A	g.143486G>A	p.G4638D	RYR1	rs118192135	38572185
3685256	29	c.13918A>G	g.38572190A>G	g.143491A>G	p.M4640V	RYR1	rs756850145	38572190
3685257	29	c.13934G>A	g.38572206G>A	g.143507G>A	p.R4645Q	RYR1	rs193922860	38572206
3685258	29	c.13990T>C	g.38572262T>C	g.143563T>C	p.C4664R	RYR1	rs759500310	38572262
3685259	29	c.13994_13995delTCinsCT	g.38572266_38572267delinsCT	g.143567_143568delinsCT	p.L4665P	RYR1	rs193922862	38572266
3685260	29	c.14002C>T	g.38573180C>T	g.144481C>T	p.P4668S	RYR1	rs193922863	38573180
3685261	29	c.14051T>C	g.38573229T>C	g.144530T>C	p.F4684S	RYR1	rs193922864	38573229
3685262	29	c.14126C>T	g.38573304C>T	g.144605C>T	p.T4709M	RYR1	rs118192140	38573304
3685263	29	c.14168G>A	g.38575957G>A	g.147258G>A	p.R4723H	RYR1	rs200766617	38575957
3685264	29	c.14186A>C	g.38577931A>C	g.149232A>C	p.H4729P	RYR1	\N	38577931
3685265	29	c.14197T>G	g.38577942T>G	g.149243T>G	p.Y4733D	RYR1	rs193922865	38577942
3685266	29	c.14201G>A	g.38577946G>A	g.149247G>A	p.G4734E	RYR1	rs193922866	38577946
3685267	29	c.14209C>T	g.38577954C>T	g.149255C>T	p.R4737W	RYR1	rs193922867	38577954
3685268	29	c.14210G>A	g.38577955G>A	g.149256G>A	p.R4737Q	RYR1	rs193922868	38577955
3685269	29	c.14270G>A	g.38578015G>A	g.149316G>A	p.R4757H	RYR1	rs768360593	38578015
779141	91	c.14387A>G	g.38580004A>G	g.151305A>G	p.Y4796C	RYR1	rs118192167	38580004
3685271	29	c.14422_14423delinsAA	g.38580039_38580040delinsAA	g.151340_151341delinsAA	p.F4808N	RYR1	\N	38580039
3685272	29	c.14424C>A	g.38580041C>A	g.151342C>A	p.F4808L	RYR1	\N	38580041
3685273	29	c.14449A>T	g.38580066A>T	g.151367A>T	p.I4817F	RYR1	rs143988412	38580066
3685274	29	c.14458G>A; c.14458G>T	g.38580075G>A; g.38580075G>T	g.151376G>A; g.151376G>T	p.G4820R; p.G4820W	RYR1	rs193922873	38580075
3685275	29	c.14471T>C	g.38580088T>C	g.151389T>C	p.L4824P	RYR1	rs193922874	38580088
779142	91	c.14477C>T	g.38580094C>T	g.151395C>T	p.T4826I	RYR1	rs121918595	38580094
779143	91	c.14497C>T	g.38580114C>T	g.151415C>T	p.H4833Y	RYR1	rs193922876	38580114
3685301	29	c.14918C>T	g.38586140C>T	g.157441C>T	p.P4973L	RYR1	rs146876145	38586140
3685302	29	c.14968A>G	g.38586190A>G	g.157491A>G	p.M4990V	RYR1	\N	38586190
3685303	29	c.15059G>C	g.38587362G>C	g.158663G>C	p.W5020S	RYR1	\N	38587362
3685279	29	c.14509C>G	g.38580126C>G	g.151427C>G	p.Q4837E	RYR1	\N	38580126
779144	91	c.14512C>G	g.38580370C>G	g.151671C>G	p.L4838V	RYR1	rs193922878	38580370
3685281	29	c.14524G>A	g.38580382G>A	g.151683G>A	p.V4842M	RYR1	rs193922879	38580382
3685282	29	c.14539G>C	g.38580397G>C	g.151698G>C	p.V4847L	RYR1	\N	38580397
779145	91	c.14545G>A	g.38580403G>A	g.151704G>A	p.V4849I	RYR1	rs118192168	38580403
3685284	29	c.14558C>T	g.38580416C>T	g.151717C>T	p.T4853I	RYR1	\N	38580416
3685285	29	c.14567C>G	g.38580425C>G	g.151726C>G	p.A4856G	RYR1	rs193922880	38580425
779146	91	c.14582G>A	g.38580440G>A	g.151741G>A	p.R4861H	RYR1	rs63749869	38580440
779484	91	-364C>T	g.233759924C>T	g.175181C>T	5' Flanking	UGT1A1	rs887829	233759924
1000510	82	CA(TA)5TAA CA(TA)6TAA CA(TA)7TAA CA(TA)8TAA	g.233760235TA[6]; g.233760235TA[7]; g.233760235TA[8]; g.233760235TA[9]	g.175492TA[6]; g.175492TA[7]; g.175492TA[8]; g.175492TA[9]	5' Flanking	UGT1A1	rs3064744	233760235
779486	91	211G>A	g.233760498G>A	g.175755G>A	p.G71R	UGT1A1	rs4148323	233760498
779487	91	686C>A	g.233760973C>A	g.176230C>A	p.P229Q	UGT1A1	rs35350960	233760973
779506	91	-1639G>A	g.31096368C>T	g.3588G>A	5' region	VKORC1	rs9923231	31096368
779040	91	-1595G>A	g.39248147C>T	g.1825G>A	unknown (upstream)	IFNL3	rs12979860	39248147
3685278	29	c.14510delA	g.38580127delA	g.151428delA	p.Q4837Rfs*3	RYR1	rs193922877	38580127
3685287	29	c.14581C>T	g.38580439C>T	g.151740C>T	p.R4861C	RYR1	rs118192181	38580439
3685288	29	c.14627A>G	g.38580485A>G	g.151786A>G	p.K4876R	RYR1	rs113210953	38580485
3685289	29	c.14639T>C	g.38580497T>C	g.151798T>C	p.M4880T	RYR1	rs193922883	38580497
3685290	29	c.14678G>A	g.38584974G>A	g.156275G>A	p.R4893Q	RYR1	rs118192151	38584974
3685291	29	c.14680G>A	g.38584976G>A	g.156277G>A	p.A4894T	RYR1	rs193922888	38584976
779147	91	c.14693T>C	g.38584989T>C	g.156290T>C	p.I4898T	RYR1	rs118192170	38584989
3685293	29	c.14782A>G	g.38585078A>G	g.156379A>G	p.I4928V	RYR1	\N	38585078
3685294	29	c.14803G>A	g.38585099G>A	g.156400G>A	p.G4935S	RYR1	\N	38585099
3685295	29	c.14813T>C	g.38585947T>C	g.157248T>C	p.I4938T	RYR1	rs111657878	38585947
3685296	29	c.14814C>G	g.38585948C>G	g.157249C>G	p.I4938M	RYR1	rs118192159	38585948
3685299	29	c.14825G>T	g.38585959G>T	g.157260G>T	p.G4942V	RYR1	rs193922896	38585959
3685300	29	c.14879T>A	g.38586101T>A	g.157402T>A	p.F4960Y	RYR1	rs193922898	38586101
779349	91	1A>G	g.18149127T>C	g.11017A>G	p.M1V	TPMT	rs9333569	18149127
779350	91	2T>C	g.18149126A>G	g.11018T>C	p.M1T	TPMT	rs267607275	18149126
779351	91	83A>T	g.18149045T>A	g.11099A>T	p.E28V	TPMT	rs72552742	18149045
779352	91	95_96insA	g.18149032_18149033insT	g.11111_11112insA	p.K32KfsX58	TPMT	rs759836180	18149032
779353	91	106G>A	g.18149022C>T	g.11122G>A	p.G36S	TPMT	rs750424422	18149022
779354	91	124C>G	g.18149004G>C	g.11140C>G	p.Q42E	TPMT	\N	18149004
779355	91	146T>C	g.18147910A>G	g.12234T>C	p.L49S	TPMT	rs72552740	18147910
779356	91	200T>C	g.18147856A>G	g.12288T>C	p.F67S	TPMT	\N	18147856
779357	91	205C>G	g.18147851G>C	g.12293C>G	p.L69V	TPMT	rs200591577	18147851
779358	91	211G>A	g.18147845C>T	g.12299G>A	p.G71R	TPMT	rs777686348	18147845
779359	91	218C>T	g.18147838G>A	g.12306C>T	p.A73V	TPMT	rs281874771	18147838
779360	91	234G>T	g.18143728C>A	g.16416G>T	p.W78C	TPMT	rs1256618794	18143728
779361	91	238G>C	g.18143724C>G	g.16420G>C	p.A80P	TPMT	rs1800462	18143724
779362	91	244C>T	g.18143718G>A	g.16426C>T	p.R82W	TPMT	rs111901354	18143718
779363	91	262G>A	g.18143700C>T	g.16444G>A	p.G88S	TPMT	rs753545734	18143700
779364	91	319T>G	g.18143643A>C	g.16501T>G	p.Y107D	TPMT	\N	18143643
779366	91	349G>C	g.18143613C>G	g.16531G>C	p.G117R	TPMT	\N	18143613
779367	91	356A>C	g.18143606T>G	g.16538A>C	p.K119T	TPMT	rs151149760	18143606
779368	91	365A>C	g.18143597T>G	g.16547A>C	p.K122T	TPMT	\N	18143597
779369	91	374C>T	g.18139710G>A	g.20434C>T	p.S125L	TPMT	rs200220210	18139710
779370	91	395G>A	g.18139689C>T	g.20455G>A	p.C132Y	TPMT	rs72552738	18139689
779371	91	430G>C	g.18139027C>G	g.21117G>C	p.G144R	TPMT	rs72552737	18139027
779372	91	460G>A	g.18138997C>T	g.21147G>A	p.A154T	TPMT	rs1800460	18138997
779373	91	487C>T	g.18138970G>A	g.21174C>T	p.R163C	TPMT	rs112339338	18138970
779374	91	488G>A; 488G>C	g.18138969C>T; g.18138969C>G	g.21175G>A; g.21175G>C	p.R163H; p.R163P	TPMT	rs144041067	18138969
779375	91	495-1G>A	g.18133890C>T	g.26254G>A	\N	TPMT	rs9333570	18133890
779376	91	497A>G	g.18133887T>C	g.26257A>G	p.Y166C	TPMT	rs201695576	18133887
779377	91	500C>G	g.18133884G>C	g.26260C>G	p.A167G	TPMT	rs74423290	18133884
779380	91	539A>T	g.18133845T>A	g.26299A>T	p.Y180F	TPMT	rs75543815	18133845
779381	91	595G>A	g.18132163C>T	g.27981G>A	p.V199I	TPMT	\N	18132163
779382	91	611T>C	g.18132147A>G	g.27997T>C	p.I204T	TPMT	rs79901429	18132147
779383	91	622T>C	g.18132136A>G	g.28008T>C	p.F208L	TPMT	rs72556347	18132136
779384	91	626-1G>A	g.18130781C>T	g.29363G>A	\N	TPMT	rs1800584	18130781
779385	91	634T>C	g.18130772A>G	g.29372T>C	p.C212R	TPMT	rs377085266	18130772
779386	91	644G>A	g.18130762C>T	g.29382G>A	p.R215H	TPMT	rs56161402	18130762
779387	91	648T>A	g.18130758A>T	g.29386T>A	p.C216X	TPMT	rs398122996	18130758
779388	91	677G>A	g.18130729C>T	g.29415G>A	p.R226Q	TPMT	rs139392616	18130729
779389	91	681T>G	g.18130725A>C	g.29419A>C	p.H227Q	TPMT	rs72552736	18130725
779390	91	712A>G	g.18130694T>C	g.29450A>G	p.K238E	TPMT	rs150900439	18130694
779391	91	719A>G;719A>C	g.18130687T>C; g.18130687T>G	g.29457A>G; g.29457A>C	p.Y240C; p.Y240S	TPMT	rs1142345	18130687
\.


--
-- Data for Name: statistic; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.statistic (createdon, stattype, statvalue) FROM stdin;
2025-03-17 09:33:26.107	COUNT_GUIDELINE_PUBLICATIONS	45
2025-03-17 09:33:26.107	COUNT_PAIRS	573
2025-03-17 09:33:26.107	SIZE_DB	1423774511
2025-03-17 09:33:26.107	COUNT_FILES_PUBLISHED	776
2025-03-17 09:33:26.107	COUNT_DB_ROWS	475353
2025-03-17 09:33:26.107	COUNT_GUIDELINES	30
2025-03-17 09:33:26.107	COUNT_DB_TABLES	24
2025-03-17 09:33:26.107	COUNT_DB_DL	105
2025-03-17 09:33:26.107	SIZE_DB_TRANSFER	11252883
2025-03-17 09:33:26.107	COUNT_ALL_RELEASE	30
2025-03-17 09:33:26.107	COUNT_RELEASE	30
2025-07-29 12:48:48.129	COUNT_DB_TABLES	24
2025-07-29 12:48:48.129	COUNT_DB_ROWS	485686
2025-07-29 12:48:48.129	COUNT_FILES_PUBLISHED	776
2025-07-29 12:48:48.129	COUNT_GUIDELINE_PUBLICATIONS	45
2025-07-29 12:48:48.129	COUNT_GUIDELINES	30
2025-07-29 12:48:48.129	SIZE_DB	1436046127
2025-07-29 12:48:48.129	COUNT_PAIRS	573
2025-07-29 12:48:48.129	SIZE_DB_TRANSFER	91577039
2025-07-29 12:48:48.129	COUNT_ALL_RELEASE	71
2025-07-29 12:48:48.129	COUNT_DB_DL	1285
2025-07-29 12:48:48.129	COUNT_RELEASE	64
2025-07-29 12:50:14.329	COUNT_GUIDELINES	30
2025-07-29 12:50:14.329	COUNT_PAIRS	573
2025-07-29 12:50:14.329	COUNT_FILES_PUBLISHED	776
2025-07-29 12:50:14.329	SIZE_DB	1436046127
2025-07-29 12:50:14.329	COUNT_GUIDELINE_PUBLICATIONS	45
2025-07-29 12:50:14.329	COUNT_DB_ROWS	485686
2025-07-29 12:50:14.329	COUNT_DB_TABLES	24
2025-07-29 12:50:14.329	COUNT_DB_DL	1285
2025-07-29 12:50:14.329	SIZE_DB_TRANSFER	91577039
2025-07-29 12:50:14.329	COUNT_ALL_RELEASE	71
2025-07-29 12:50:14.329	COUNT_RELEASE	64
\.


--
-- Data for Name: term; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.term (id, category, term, functionaldef, geneticdef, loinc, version) FROM stdin;
110037	Allele functional status: all genes	Increased function	Function greater than normal function	N/A	\N	1
110038	Allele functional status: all genes	Normal function	Fully functional/wild-type	N/A	\N	1
110039	Allele functional status: all genes	Decreased function	Function less than normal function	N/A	\N	1
110040	Allele functional status: all genes	No function	Nonfunctional	N/A	\N	1
110041	Allele functional status: all genes	Unknown function	No literature describing function or the allele is novel	N/A	\N	1
110042	Allele functional status: all genes	Uncertain function	Literature supporting function is conflicting or weak	N/A	\N	1
110043	Phenotype: drug-metabolizing enzymes	Ultrarapid metabolizer	Increased enzyme activity compared to rapid metabolizers	Two increased function alleles, or more than 2 normal function alleles	\N	1
110044	Phenotype: drug-metabolizing enzymes	Rapid metabolizer	Increased enzyme activity compared to normal metabolizers but less than ultrarapid metabolizers	Combinations of normal function and increased function alleles	\N	1
110045	Phenotype: drug-metabolizing enzymes	Normal metabolizer	Fully functional enzyme activity	Combinations of normal function and decreased function alleles	\N	1
110046	Phenotype: drug-metabolizing enzymes	Intermediate metabolizer	Decreased enzyme activity (activity between normal and poor metabolizer)	Combinations of normal function, decreased function, and/or no function alleles	\N	1
110047	Phenotype: drug-metabolizing enzymes	Poor metabolizer	Little to no enzyme activity	Combination of no function alleles and/ or decreased function alleles	\N	1
110048	Phenotype: transporters	Increased function	Increased transporter function compared to normal function. 	One or more increased function alleles	\N	1
110049	Phenotype: transporters	Normal function	Fully functional transporter function 	Combinations of normal function and/ or decreased function alleles	\N	1
110050	Phenotype: transporters	Decreased function	Decreased transporter function (function between normal and poor function) 	Combinations of normal function, decreased function, and/or no function alleles	\N	1
110051	Phenotype: transporters	Poor function	Little to no transporter function	Combination of no function alleles and/ or decreased function alleles	\N	1
110052	Phenotype: high-risk genotype status	Positive	Detection of high-risk allele	Homozygous or heterozygous for high-risk allele	\N	1
110053	Phenotype: high-risk genotype status	Negative	High-risk allele not detected	No copies of high-risk allele	\N	1
\.


--
-- Data for Name: test_alert; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.test_alert (id, population, cdscontext, genes, phenotype, activityscore, allelestatus, lookupkey, drugid, alerttext, version) FROM stdin;
6349766	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6349767	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349768	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349769	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349770	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349771	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349772	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349773	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349774	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349775	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349977	general	No CDS	{UGT1A1}	{"UGT1A1": "Indeterminate"}	{}	{}	{"UGT1A1": "Indeterminate"}	RxNorm:343047	{n/a}	1
6349776	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6349777	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6349778	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6349779	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6349780	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6349781	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6349782	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6349783	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349784	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6350213	general	No CDS	{CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{}	{}	{"CYP2C19": "Normal Metabolizer"}	RxNorm:32968	{n/a}	1
6351379	aspirin <1g	No CDS	{G6PD}	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	RxNorm:1191	{n/a}	1
6349785	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6349786	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6349787	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6349788	general	Pre-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2C19 genotype may be important for amitriptyline dosing and use. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent or dose may be recommended. Please consult a clinical pharmacist for more information."}	1
6349789	general	Pre-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. Neither a CYP2D6 nor CYP2C19 genotype appears to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349790	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349791	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349792	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349793	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
6349794	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349795	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349796	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349797	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349798	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349799	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349800	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349801	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349802	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349803	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Indeterminate"}	RxNorm:704	{n/a}	1
6349804	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349805	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349806	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349807	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349808	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349809	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349810	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349811	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349812	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349813	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349814	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349815	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349816	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6351024	general	No CDS	{CYP2B6,CYP2C19}	{"CYP2B6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{}	{}	{"CYP2B6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	RxNorm:36437	{n/a}	1
6349817	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349818	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349819	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
6349820	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
6349821	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
6349822	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
6349823	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
6349824	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349825	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349826	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349827	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349828	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349829	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349841	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
6349830	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349831	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349832	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349833	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349834	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349835	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349836	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349837	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349838	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349839	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.Please consult a clinical pharmacist for more information."}	1
6349840	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349842	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
6349843	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
6349844	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
6349845	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
6349846	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349847	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349848	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349849	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349850	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349851	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349852	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349978	general	Pre-test	{SLCO1B1}	{"SLCO1B1": "No Result"}	{}	{}	{"SLCO1B1": "No Result"}	RxNorm:83367	{"SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information."}	1
6349853	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349854	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349855	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349856	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349857	general	Pre-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349858	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349859	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349860	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349861	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349862	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349927	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349863	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349864	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349865	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349866	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349867	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349868	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349869	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349870	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349871	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349872	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349979	general	No CDS	{SLCO1B1}	{"SLCO1B1": "Increased Function"}	{}	{}	{"SLCO1B1": "Increased Function"}	RxNorm:83367	{n/a}	1
6349873	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349874	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349875	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349876	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{n/a}	1
6349877	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349878	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349879	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349880	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349881	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349882	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6349883	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349884	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349885	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349886	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{n/a}	1
6349887	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{n/a}	1
6349888	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349889	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349890	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349891	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349892	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349893	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349894	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349980	general	No CDS	{SLCO1B1}	{"SLCO1B1": "Normal Function"}	{}	{}	{"SLCO1B1": "Normal Function"}	RxNorm:83367	{n/a}	1
6351380	aspirin <1g	No CDS	{G6PD}	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	RxNorm:1191	{n/a}	1
6349895	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349896	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349897	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
6349898	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349899	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349900	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349901	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349902	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349903	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349904	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349905	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6351577	Hydrocodone	No CDS	{CYP2D6}	{}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0"}	RxNorm:5489	{n/a}	1
6349906	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349907	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349908	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6349909	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349910	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349911	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349912	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349913	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349914	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349915	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6351578	Hydrocodone	No CDS	{CYP2D6}	{}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0"}	RxNorm:5489	{n/a}	1
6349916	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349917	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
6349918	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349919	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349920	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349921	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349922	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349923	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349924	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349925	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349926	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350819	non-H.pylori_erosive	Pre-test	{CYP2C19}	{"CYP2C19": "No Result"}	{}	{}	{"CYP2C19": "No Result"}	RxNorm:17128	{"CYP2C19 genotype may be important for this proton pump inhibitor's dosing. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information."}	1
6349928	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349929	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349930	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349931	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349932	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, this patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349933	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
6349934	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
6349935	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
6349936	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
6349937	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{n/a}	1
6349938	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{n/a}	1
6349962	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349939	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349940	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349941	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349942	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349943	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349944	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349945	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349946	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349947	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349948	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349949	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349950	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349951	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{n/a}	1
6349952	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349953	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349954	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349955	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349956	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349957	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
6349958	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
6349959	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
6349960	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349961	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349963	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349964	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349965	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349966	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349967	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349968	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349969	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349970	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6349971	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349972	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
6349973	general	Pre-test	{UGT1A1}	{"UGT1A1": "No Result"}	{}	{}	{"UGT1A1": "No Result"}	RxNorm:343047	{"UGT1A1 genetic status may be predictive of cosmetic jaundice with this medication. A UGT1A1 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information."}	1
6349974	general	No CDS	{UGT1A1}	{"UGT1A1": "Normal Metabolizer"}	{}	{}	{"UGT1A1": "Normal Metabolizer"}	RxNorm:343047	{n/a}	1
6349975	general	No CDS	{UGT1A1}	{"UGT1A1": "Intermediate Metabolizer"}	{}	{}	{"UGT1A1": "Intermediate Metabolizer"}	RxNorm:343047	{n/a}	1
6349976	general	Post-test	{UGT1A1}	{"UGT1A1": "Poor Metabolizer"}	{}	{}	{"UGT1A1": "Poor Metabolizer"}	RxNorm:343047	{"This patient is predicted to be a UGT1A1 poor metabolizer and may be at an increased risk of developing jaundice with atazanavir use. Consider an alternative agent particularly if jaundice would be of concern to the patient. Please consult a clinical pharmacist for more information."}	1
6349981	general	Post-test	{SLCO1B1}	{"SLCO1B1": "Decreased Function"}	{}	{}	{"SLCO1B1": "Decreased Function"}	RxNorm:83367	{"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."}	1
6349982	general	Post-test	{SLCO1B1}	{"SLCO1B1": "Possible Decreased Function"}	{}	{}	{"SLCO1B1": "Possible Decreased Function"}	RxNorm:83367	{"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."}	1
6349983	general	Post-test	{SLCO1B1}	{"SLCO1B1": "Poor Function"}	{}	{}	{"SLCO1B1": "Poor Function"}	RxNorm:83367	{"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."}	1
6349984	general	No CDS	{SLCO1B1}	{"SLCO1B1": "Indeterminate"}	{}	{}	{"SLCO1B1": "Indeterminate"}	RxNorm:83367	{n/a}	1
6349985	general	Pre-test	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "No *31:01 result on file", "HLA-B": "No *15:02 result on file"}	{"HLA-A": "No *31:01 result on file", "HLA-B": "No *15:02 result on file"}	RxNorm:2002	{"HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. Neither a HLA-B*15:02 nor HLA-A*31:01 genotype appears to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349986	general	Post-test	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "*31:01 positive", "HLA-B": "No *15:02 result on file"}	{"HLA-A": "*31:01 positive", "HLA-B": "No *15:02 result on file"}	RxNorm:2002	{"HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-A*31:01 positive and may be at an increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and maculopapular exanthema (MPE). If the patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine. If the patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction. The latency period for cutaneous adverse drug reactions is short (< 8 weeks); therefore, if the patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine. A HLA-B*15:02 genotype does not appear to have been ordered for this patient. HLA-B*15:02 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6349987	general	Pre-test	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "*31:01 negative", "HLA-B": "No *15:02 result on file"}	{"HLA-A": "*31:01 negative", "HLA-B": "No *15:02 result on file"}	RxNorm:2002	{"HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-A*31:01 negative. There is no reason to alter carbamazepine therapy based on the HLA-A*31:01 result. Because a HLA-B*15:02 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349988	general	Post-test	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "No *31:01 result on file", "HLA-B": "*15:02 positive"}	{"HLA-A": "No *31:01 result on file", "HLA-B": "*15:02 positive"}	RxNorm:2002	{"HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-B*15:02 positive and may be at an increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). If the patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine. The latency period for SJS/TEN is short (< 8 weeks); therefore, if the patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine. A HLA-A*31:01 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information."}	1
6349989	general	Post-test	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "*31:01 positive", "HLA-B": "*15:02 positive"}	{"HLA-A": "*31:01 positive", "HLA-B": "*15:02 positive"}	RxNorm:2002	{"HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-B*15:02 positive and HLA-A*31:01 positive and may be at an increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and maculopapular exanthema (MPE). If the patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine. The latency period for cutaneous adverse drug reactions is short (< 8 weeks); therefore, if the patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine. Please consult a clinical pharmacist for more information."}	1
6349990	general	Post-test	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "*31:01 negative", "HLA-B": "*15:02 positive"}	{"HLA-A": "*31:01 negative", "HLA-B": "*15:02 positive"}	RxNorm:2002	{"HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-B*15:02 positive and HLA-A*31:01 negative. Based on the HLA-B*15:02 result, the patient may be at an increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). If the patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine. The latency period for cutaneous adverse drug reactions is short (< 8 weeks); therefore, if the patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine. Please consult a clinical pharmacist for more information."}	1
6349991	general	Pre-test	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "No *31:01 result on file", "HLA-B": "*15:02 negative"}	{"HLA-A": "No *31:01 result on file", "HLA-B": "*15:02 negative"}	RxNorm:2002	{"HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-B*15:02 negative. There is no reason to alter carbamazepine therapy based on the HLA-B*15:02 result. Because a HLA-A*31:01 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6349992	general	Post-test	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "*31:01 positive", "HLA-B": "*15:02 negative"}	{"HLA-A": "*31:01 positive", "HLA-B": "*15:02 negative"}	RxNorm:2002	{"HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-B*15:02 negative and HLA-A*31:01 positive. Based on the HLA-A*31:01 result, the patient may be at an increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and maculopapular exanthema (MPE). If the patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine. If the patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction. The latency period for cutaneous adverse drug reactions is short (< 8 weeks); therefore, if the patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine. Please consult a clinical pharmacist for more information."}	1
6349993	general	No CDS	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "*31:01 negative", "HLA-B": "*15:02 negative"}	{"HLA-A": "*31:01 negative", "HLA-B": "*15:02 negative"}	RxNorm:2002	{n/a}	1
6349994	general	Post-test	{CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{}	{}	{"CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2556	{"Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram is clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose. Please consult a clinical pharmacist for more information."}	1
6349995	general	Pre-test	{CYP2C19}	{"CYP2C19": "No Result"}	{}	{}	{"CYP2C19": "No Result"}	RxNorm:2556	{"CYP2C19 genotype may be important for the use of citalopram. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information."}	1
6349996	general	Post-test	{CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{}	{}	{"CYP2C19": "Rapid Metabolizer"}	RxNorm:2556	{"Based on the genotype result, this patient is predicted to be a CYP2C19 rapid metabolizer and may be at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Initiate therapy with recommended starting dose. If patient does not adequately respond, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information."}	1
6349997	general	No CDS	{CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{}	{}	{"CYP2C19": "Normal Metabolizer"}	RxNorm:2556	{n/a}	1
6349998	general	Post-test	{CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{}	{}	{"CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2556	{"Based on the genotype result, this patient is predicted to be a likely CYP2C19 intermediate metabolizer and is at risk for higher plasma concentrations and increased probability of side effects with standard dosing. Initiate therapy with recommended starting dose, but consider a slower titration schedule and lower maintenance dose. Please consult a clinical pharmacist for more information."}	1
6349999	general	Post-test	{CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{}	{}	{"CYP2C19": "Intermediate Metabolizer"}	RxNorm:2556	{"Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer and is at risk for higher plasma concentrations and increased probability of side effects with standard dosing. Initiate therapy with recommended starting dose, but consider a slower titration schedule and lower maintenance dose. Please consult a clinical pharmacist for more information."}	1
6350000	general	Post-test	{CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{}	{}	{"CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2556	{"Based on the genotype result, this patient is predicted to be a likely CYP2C19 poor metabolizer and is at risk for higher plasma concentrations and increased probability of side effects with standard dosing. Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram is clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose. Please consult a clinical pharmacist for more information."}	1
6350001	general	Post-test	{CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{}	{}	{"CYP2C19": "Poor Metabolizer"}	RxNorm:2556	{"Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer and is at risk for higher plasma concentrations and increased probability of side effects with standard dosing. Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram is clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose. Please consult a clinical pharmacist for more information."}	1
6350002	general	No CDS	{CYP2C19}	{"CYP2C19": "Indeterminate"}	{}	{}	{"CYP2C19": "Indeterminate"}	RxNorm:2556	{n/a}	1
6350003	general	Pre-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2C19 genotype may be important for clomipramine dosing and use. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent or dose may be recommended. Please consult a clinical pharmacist for more information."}	1
6351579	Hydrocodone	No CDS	{CYP2D6}	{}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75"}	RxNorm:5489	{n/a}	1
6350004	general	Pre-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. Neither a CYP2D6 nor CYP2C19 genotype appears to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350005	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6350006	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6350007	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6350008	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6350009	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6350010	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6350011	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6350012	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6350228	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350013	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6350014	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6350015	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6350016	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
6350017	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
6350018	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350019	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350020	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350021	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350022	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350023	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350311	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{n/a}	1
6351580	Hydrocodone	No CDS	{CYP2D6}	{}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0"}	RxNorm:5489	{n/a}	1
6350024	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350025	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350026	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350027	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6350028	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350029	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350030	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350031	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350032	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350033	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350034	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350035	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350036	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
6350037	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350038	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350039	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350040	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350041	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350042	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350043	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350054	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350044	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350045	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350046	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350047	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350048	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350049	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350050	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350051	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350052	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350053	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
6350067	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
6351581	Hydrocodone	No CDS	{CYP2D6}	{}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25"}	RxNorm:5489	{n/a}	1
6350055	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350056	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350057	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350058	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350059	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350060	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350061	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350062	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350063	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350064	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350065	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
6350066	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
6351582	Hydrocodone	No CDS	{CYP2D6}	{}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5"}	RxNorm:5489	{n/a}	1
6350068	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350069	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350070	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350071	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350072	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350073	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Indeterminate"}	RxNorm:2597	{n/a}	1
6350074	general	Pre-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350075	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350076	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350077	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350078	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6351583	Hydrocodone	No CDS	{CYP2D6}	{}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0"}	RxNorm:5489	{n/a}	1
6350079	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350080	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350081	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350082	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350083	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350084	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350085	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350086	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
6350087	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
6350088	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
6350089	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
6350836	general	Pre-test	{RYR1,CACNA1S}	{"RYR1": "No Result", "CACNA1S": "No Result"}	{}	{}	{"RYR1": "No Result", "CACNA1S": "No Result"}	RxNorm:6857	{"Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use."}	1
6350090	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350091	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.Please consult a clinical pharmacist for more information."}	1
6350092	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350093	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350094	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350095	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350096	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6350097	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350098	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350099	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350837	general	No CDS	{RYR1,CACNA1S}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "Uncertain Susceptibility"}	{}	{}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "Uncertain Susceptibility"}	RxNorm:6857	{n/a}	1
6351618	general	No CDS	{G6PD}	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	RxNorm:6572	{n/a}	1
6350100	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350101	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350102	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350103	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350104	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350105	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350106	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350107	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350108	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350109	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6351619	general	No CDS	{G6PD}	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	RxNorm:6572	{n/a}	1
6350110	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350111	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350112	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350113	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350114	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350115	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350116	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350117	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350118	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350119	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6351781	general	No CDS	{G6PD}	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	RxNorm:10178	{n/a}	1
6350120	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350121	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350122	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350123	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350124	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350125	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350126	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350127	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350128	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350129	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350838	general	Pre-test	{CYP2D6}	{}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result"}	RxNorm:7531	{"CYP2D6 genetic status may be important for nortriptyline dosing and use. A CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350130	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350131	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350132	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350133	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350134	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350135	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350136	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350137	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350138	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350139	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6351675	general	No CDS	{CYP2D6}	{"CYP2D6": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5"}	RxNorm:6918	{n/a}	1
6350140	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350141	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350142	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350143	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350144	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350145	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350146	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350147	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350148	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350149	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350150	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350151	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350152	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350153	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350154	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350155	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350156	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350157	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350158	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350159	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350160	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6351676	general	No CDS	{CYP2D6}	{"CYP2D6": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25"}	RxNorm:6918	{n/a}	1
6350161	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350162	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350163	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350164	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350165	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{n/a}	1
6350166	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350167	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350168	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350169	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350170	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350184	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
6350171	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350172	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350173	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350174	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350175	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350176	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350177	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{n/a}	1
6350178	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{n/a}	1
6350179	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{n/a}	1
6350180	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{n/a}	1
6350181	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{n/a}	1
6350182	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
6350183	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
6350210	general	Pre-test	{CYP2C19}	{"CYP2C19": "No Result"}	{}	{}	{"CYP2C19": "No Result"}	RxNorm:32968	{"The patient's CYP2C19 genotype may be important for choice of antiplatelet therapy. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information."}	1
6350185	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
6350186	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, this patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350187	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350188	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
6350189	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350190	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350191	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350192	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350193	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350194	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350195	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350211	general	No CDS	{CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{}	{}	{"CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:32968	{n/a}	1
6350212	general	No CDS	{CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{}	{}	{"CYP2C19": "Rapid Metabolizer"}	RxNorm:32968	{n/a}	1
6350196	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350197	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350198	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350199	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350200	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
6350201	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
6350202	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
6350203	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
6350204	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
6350205	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350206	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350207	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350208	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350209	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350214	general	Post-test	{CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{}	{}	{"CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:32968	{"Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer. Avoid standard dose clopidogrel (75 mg) if possible due to the risk of therapeutic failure in patients that had a recent acute coronary syndrome and/or a percutaneous coronary intervention, or a neurovascular indication for clopidogrel. Consider use of an alternative antiplatelet agent at standard dose if no contraindication. Prasugrel is contraindicated in patients with a history of transient ischemic attack or stroke. Please consult a clinical pharmacist for more information."}	1
6350215	general	Post-test	{CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{}	{}	{"CYP2C19": "Intermediate Metabolizer"}	RxNorm:32968	{"Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer. Avoid standard dose clopidogrel (75 mg) if possible due to the risk of therapeutic failure in patients that had a recent acute coronary syndrome and/or a percutaneous coronary intervention, or a neurovascular indication for clopidogrel. Consider use of an alternative antiplatelet agent at standard dose if no contraindication. Prasugrel is contraindicated in patients with a history of transient ischemic attack or stroke. Please consult a clinical pharmacist for more information."}	1
6350216	general	Post-test	{CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{}	{}	{"CYP2C19": "Likely Poor Metabolizer"}	RxNorm:32968	{"Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer. Avoid clopidogrel if possible due to the risk of therapeutic failure. Use an alternative antiplatelet agent at standard dose if no contraindication. Prasugrel is contraindicated in patients with a history of transient ischemic attack or stroke. Please consult a clinical pharmacist for more information."}	1
6350217	general	Post-test	{CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{}	{}	{"CYP2C19": "Poor Metabolizer"}	RxNorm:32968	{"Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer. Avoid clopidogrel if possible due to the risk of therapeutic failure. Use an alternative antiplatelet agent at standard dose if no contraindication. Prasugrel is contraindicated in patients with a history of transient ischemic attack or stroke. Please consult a clinical pharmacist for more information."}	1
6350218	general	No CDS	{CYP2C19}	{"CYP2C19": "Indeterminate"}	{}	{}	{"CYP2C19": "Indeterminate"}	RxNorm:32968	{n/a}	1
6350219	general	Post-test	{RYR1,CACNA1S}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "Malignant Hyperthermia Susceptibility"}	{}	{}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "Malignant Hyperthermia Susceptibility"}	RxNorm:27340	{"Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information."}	1
6350220	general	Post-test	{RYR1,CACNA1S}	{"RYR1": "Malignant Hyperthermia Susceptibility", "CACNA1S": "Uncertain Susceptibility"}	{}	{}	{"RYR1": "Malignant Hyperthermia Susceptibility", "CACNA1S": "Uncertain Susceptibility"}	RxNorm:27340	{"Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information."}	1
6350221	general	Pre-test	{RYR1,CACNA1S}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "No Result"}	{}	{}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "No Result"}	RxNorm:27340	{"Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use."}	1
6350222	general	Pre-test	{RYR1,CACNA1S}	{"RYR1": "No Result", "CACNA1S": "Uncertain Susceptibility"}	{}	{}	{"RYR1": "No Result", "CACNA1S": "Uncertain Susceptibility"}	RxNorm:27340	{"Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use."}	1
6350223	general	Pre-test	{RYR1,CACNA1S}	{"RYR1": "No Result", "CACNA1S": "No Result"}	{}	{}	{"RYR1": "No Result", "CACNA1S": "No Result"}	RxNorm:27340	{"Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use."}	1
6350224	general	No CDS	{RYR1,CACNA1S}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "Uncertain Susceptibility"}	{}	{}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "Uncertain Susceptibility"}	RxNorm:27340	{n/a}	1
6350225	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and may experience higher than expected plasma concentrations of desipramine resulting in an increased the probability of adverse reactions. Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350226	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350227	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350229	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350230	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25"}	RxNorm:3247	{n/a}	1
6350231	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0"}	RxNorm:3247	{n/a}	1
6350232	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75"}	RxNorm:3247	{n/a}	1
6350233	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5"}	RxNorm:3247	{n/a}	1
6350234	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25"}	RxNorm:3247	{n/a}	1
6350235	general	Pre-test	{CYP2D6}	{}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result"}	RxNorm:3247	{"CYP2D6 genetic status may be important for desipramine dosing and use. A CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350236	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350237	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350238	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350239	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350240	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350241	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350242	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350243	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and may experience higher than expected plasma concentrations of desipramine resulting in an increased the probability of adverse reactions. Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350244	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and may experience higher than expected plasma concentrations of desipramine resulting in an increased the probability of adverse reactions. Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350245	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and may experience higher than expected plasma concentrations of desipramine resulting in an increased the probability of adverse reactions. Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350246	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 poor metabolizer and may experience higher than expected plasma concentrations of desipramine resulting in an increased the probability of adverse reactions. Consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350247	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a"}	RxNorm:3247	{n/a}	1
6350248	H.pylori_erosive eso	Post-test	{CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{}	{}	{"CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and is at risk for decreased plasma concentrations and therapeutic failure with standard dosing. Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information."}	1
6350249	H.pylori_erosive eso	Post-test	{CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{}	{}	{"CYP2C19": "Rapid Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 rapid metabolizer. The patient may be at risk for therapeutic failure at standard doses. Consider increasing the dose by 50-100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information."}	1
6350250	H.pylori_erosive eso	Pre-test	{CYP2C19}	{"CYP2C19": "No Result"}	{}	{}	{"CYP2C19": "No Result"}	RxNorm:816346	{"CYP2C19 genotype may be important for this proton pump inhibitor's dosing. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information."}	1
6350251	H.pylori_erosive eso	Post-test	{CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{}	{}	{"CYP2C19": "Normal Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 normal metabolizer. The patient may be at risk for therapeutic failure at standard doses. Consider increasing the dose by 50-100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information."}	1
6350252	H.pylori_erosive eso	Post-test	{CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{}	{}	{"CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information."}	1
6350253	H.pylori_erosive eso	Post-test	{CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{}	{}	{"CYP2C19": "Intermediate Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information."}	1
6350254	H.pylori_erosive eso	Post-test	{CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{}	{}	{"CYP2C19": "Likely Poor Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information."}	1
6350255	H.pylori_erosive eso	Post-test	{CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{}	{}	{"CYP2C19": "Poor Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information."}	1
6350256	H.pylori_erosive eso	No CDS	{CYP2C19}	{"CYP2C19": "Indeterminate"}	{}	{}	{"CYP2C19": "Indeterminate"}	RxNorm:816346	{n/a}	1
6350257	non-H.pylori_erosive	Pre-test	{CYP2C19}	{"CYP2C19": "No Result"}	{}	{}	{"CYP2C19": "No Result"}	RxNorm:816346	{"CYP2C19 genotype may be important for this proton pump inhibitor's dosing. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information."}	1
6350258	non-H.pylori_erosive	Post-test	{CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{}	{}	{"CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and is at risk for decreased plasma concentrations and therapeutic failure with standard dosing. Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information."}	1
6350259	non-H.pylori_erosive	No CDS	{CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{}	{}	{"CYP2C19": "Rapid Metabolizer"}	RxNorm:816346	{n/a}	1
6350260	non-H.pylori_erosive	No CDS	{CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{}	{}	{"CYP2C19": "Normal Metabolizer"}	RxNorm:816346	{n/a}	1
6350261	non-H.pylori_erosive	Post-test	{CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{}	{}	{"CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information."}	1
6351782	general	No CDS	{G6PD}	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	RxNorm:10178	{n/a}	1
6350262	non-H.pylori_erosive	Post-test	{CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{}	{}	{"CYP2C19": "Intermediate Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information."}	1
6350263	non-H.pylori_erosive	Post-test	{CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{}	{}	{"CYP2C19": "Likely Poor Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information."}	1
6350264	non-H.pylori_erosive	Post-test	{CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{}	{}	{"CYP2C19": "Poor Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information."}	1
6350265	non-H.pylori_erosive	No CDS	{CYP2C19}	{"CYP2C19": "Indeterminate"}	{}	{}	{"CYP2C19": "Indeterminate"}	RxNorm:816346	{n/a}	1
6350266	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{n/a}	1
6350267	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{n/a}	1
6350268	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350269	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350270	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350271	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350272	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{n/a}	1
6350273	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{n/a}	1
6350274	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{n/a}	1
6350275	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350839	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0"}	RxNorm:7531	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If nortriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350276	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350277	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350278	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350279	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350280	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350281	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350282	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350283	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350284	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350285	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350286	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350287	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{n/a}	1
6350288	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350289	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
6350290	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
6350291	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
6350292	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
6350293	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{n/a}	1
6350294	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{n/a}	1
6350295	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{n/a}	1
6350296	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{n/a}	1
6350297	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{n/a}	1
6350298	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350299	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, this patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350300	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350312	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350301	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350302	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350303	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350304	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350305	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350306	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350307	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350308	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350309	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350310	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350313	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350314	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350315	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350316	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350317	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350318	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350319	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350320	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350321	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350322	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350323	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350324	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350325	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350326	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350327	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350328	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350329	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350330	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350331	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350332	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350333	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350485	general	No CDS	{RYR1,CACNA1S}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "Uncertain Susceptibility"}	{}	{}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "Uncertain Susceptibility"}	RxNorm:3920	{n/a}	1
6350334	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
6350335	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350336	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350337	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350338	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350339	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350340	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350341	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350342	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350343	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350344	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350345	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350346	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350347	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350348	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350349	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350350	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350351	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350352	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350353	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350486	general	Pre-test	{CYP2C19}	{"CYP2C19": "No Result"}	{}	{}	{"CYP2C19": "No Result"}	RxNorm:321988	{"CYP2C19 genotype may be important for the use of escitalopram. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information."}	1
6350354	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350355	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350356	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350357	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
6350358	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350359	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350360	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350361	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350362	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350363	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6351677	general	No CDS	{CYP2D6}	{"CYP2D6": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0"}	RxNorm:6918	{n/a}	1
6350364	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350365	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350366	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350367	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350368	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350369	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350370	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350371	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
6350372	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
